Targeting Mitochondria in Aging-Related Diseases: Therapeutic Potential and Obstacles

Abstract

Aging is a complex biological process characterized by the functional decline of multiple cellular organelles, with mitochondrial dysfunction emerging as a predominant hallmark. Alterations in mitochondria within senescent cells primarily encompass two interrelated aspects: intrinsic mitochondrial dysfunction and compromised mitochondrial quality control systems, including mitophagy, dynamics, and biogenesis. However, a comprehensive synthesis that bridges mechanistic insights into mitochondrial dysfunction with an analysis of therapeutic obstacles remains lacking. Here, we systematically summarized the pathways leading to mitochondrial dysfunction in aging and deeply analyzed how this dysregulation, including mitochondrial DNA instability and mitochondria driving inflammation through the cGAS–STING pathway, contributed to the etiology of aging-related diseases, including muscle, bone, neurodegeneration, cardiovascular, and metabolic diseases. Additionally, we analyzed a series of mitochondrial targeted treatment strategies, from metabolism and kinetic regulation to disease-specific intervention and emerging technologies, such as mitochondrial transplantation and mitochondrial DNA base editing. Finally, we emphasized the key obstacles that must be overcome for clinical transformation, including tissue-specific mitochondrial heterogeneity. By combining the basic mechanism with the development of treatment and its potential challenges, this review provides a key perspective for promoting the emerging field of mitochondrial medicine to intervene in aging-related pathology more accurately and effectively.

Keywords

aging / mitochondria / therapy

References

[1] S. Chaib, T. Tchkonia, and J. L. Kirkland, “Cellular Senescence and Senolytics: The Path to the Clinic,” Nature Medicine 28 (2022): 1556–1568.

[2] R. C. Zhao and I. Stambler, “The Urgent Need for International Action for Anti-Aging and Disease Prevention,” Aging and Disease 11, no. 1 (2020): 212–215.

[3] S. Miwa, S. Kashyap, E. Chini, and T. von Zglinicki, “Mitochondrial Dysfunction in Cell Senescence and Aging,” The Journal of Clinical Investigation 132 (2022).

[4] J. R. Speakman, “Body Size, Energy Metabolism and Lifespan,” Journal of Experimental Biology 208 (2005): 1717–1730.

[5] D. Harman, “Aging: A Theory Based on Free Radical and Radiation Chemistry,” Gerontol 11, no. 3 (1956): 298–300.

[6] J. Y. Jang, A. Blum, J. Liu, and T. Finkel, “The Role of Mitochondria in Aging,” The Journal of Clinical Investigation 128 (2018): 3662–3670.

[7] J. Guo, X. Huang, L. Dou, et al., “Aging and Aging-Related Diseases: From Molecular Mechanisms to Interventions and Treatments,” Signal Transduction and Targeted Therapy 7 (2022).

[8] X. Feng, Y. Zheng, N. Mao, et al., “Menaquinone-4 Alleviates Hypoxic-Ischemic Brain Damage in Neonatal Rats by Reducing Mitochondrial Dysfunction via Sirt1-Pgc-1α-Tfam Signaling Pathway,” International Immunopharmacology 134 (2024): 112257.

[9] C. López-Otín, M. A. Blasco, L. Partridge, et al., “The Hallmarks of Aging,” Cell 153, no. 6 (2013): 1194–1217.

[10] C. Mantel, S. Messina-Graham, A. Moh, et al., “Mouse Hematopoietic Cell-Targeted Stat3 Deletion: Stem/Progenitor Cell Defects, Mitochondrial Dysfunction, Ros Overproduction, and a Rapid Aging-Like Phenotype,” Blood 120 (2012): 2589–2599.

[11] S. Pickles, P. Vigié, and R. J. Youle, “Mitophagy and Quality Control Mechanisms in Mitochondrial Maintenance,” Current Biology 28 (2018): R170–R185.

[12] R. H. Swerdlow, “Mitochondria and Mitochondrial Cascades in Alzheimer's Disease,” Journal of Alzheimer's Disease 62 (2018): 1403–1416.

[13] J. A. Amorim, G. Coppotelli, A. P. Rolo, et al., “Mitochondrial and Metabolic Dysfunction in Ageing and Age-Related Diseases,” Nature Reviews Endocrinology 18 (2022): 243–258.

[14] D. Bou-Teen, N. Kaludercic, D. Weissman, et al., “Mitochondrial Ros and Mitochondria-Targeted Antioxidants in the Aged Heart,” Free Radical Biology and Medicine 167 (2021): 109–124.

[15] H. W. S. Tan, G. Lu, and H.-M. Shen, “Autophagic Secretion of Mitochondria (Asm): An Alternative Way for Getting Rid of Damaged Mitochondria,” Autophagy 19, no. 2 (2022): 739–741.

[16] S. Y. Simonenko, D. A. Bogdanova, and N. A. Kuldyushev, “Emerging Roles of Vitamin B12 in Aging and Inflammation,” International Journal of Molecular Sciences 25 (2024): 5044.

[17] C. R. Martens, B. A. Denman, M. R. Mazzo, et al., “Chronic Nicotinamide Riboside Supplementation Is Well-Tolerated and Elevates Nad+ in Healthy Middle-Aged and Older Adults,” Nature Communications 9, no. 1 (2018): 1286.

[18] X.-M. Wang, H. Xiao, L.-L. Liu, et al., “Fgf21 Represses Cerebrovascular Aging via Improving Mitochondrial Biogenesis and Inhibiting P53 Signaling Pathway in an Ampk-Dependent Manner,” Experimental Cell Research 346 (2016): 147–156.

[19] A. Pearah, B. Ramatchandirin, T. Liu, et al., “Blocking Ampkαs496 Phosphorylation Improves Mitochondrial Dynamics and Hyperglycemia in Aging and Obesity,” Cell Chemical Biology 30 (2023): 1585–1600.e6.

[20] M. J. Rossman, J. R. Santos-Parker, C. A. C. Steward, et al., “Chronic Supplementation With a Mitochondrial Antioxidant (Mitoq) Improves Vascular Function in Healthy Older Adults,” Hypertension 71 (2018): 1056–1063.

[21] Y. Huang, W. Ji, J. Zhang, et al., “The Involvement of the Mitochondrial Membrane in Drug Delivery,” Acta Biomaterialia 176 (2024): 28–50.

[22] L. Chen, M. Zhou, H. Li, et al., “Mitochondrial Heterogeneity in Diseases,” Signal Transduction and Targeted Therapy 8 (2023): 311.

[23] A. Gropman and B. Chandra, “Mitochondrial Disorders: Emerging Paradigms and the Road Ahead to Personalized Medicine,” Neurotherapeutics 21 (2024): e00332.

[24] A. V. Birk, S. Liu, Y. Soong, et al., “The Mitochondrial-Targeted Compound Ss-31 Re-Energizes Ischemic Mitochondria by Interacting With Cardiolipin,” Journal of the American Society of Nephrology 24 (2013): 1250–1261.

[25] X. Zhang, Y. Gao, S. zhang, et al., “Mitochondrial Dysfunction in the Regulation of Aging and Aging-Related Diseases,” Cell Communication and Signaling 23, no. 1 (2025): 290.

[26] M. Babbar, S. Basu, B. Yang, et al., “Mitophagy and DNA Damage Signaling in Human Aging,” Mechanisms of Ageing and Development 186 (2020): 111207.

[27] S. Nag, O. Mitra, B. Maturi, et al., “Autophagy and Mitophagy as Potential Therapeutic Targets in Diabetic Heart Condition: Harnessing the Power of Nanotheranostics,” Asian Journal of Pharmaceutical Sciences 19 (2024): 100927.

[28] L. Yanping, H. Hengjing, T. Huifang, et al., “Homocysteine Promotes Cardiomyocyte Hypertrophy Through Inhibiting Β-Catenin/Fundc1 Mediated Mitophagy,” Scientific Reports (2025).

[29] X. Cen, M. Zhang, M. Zhou, et al., “Mitophagy Regulates Neurodegenerative Diseases,” Cells 10 (2021): 1876.

[30] D. P. Panigrahi, P. P. Praharaj, C. S. Bhol, et al., “The Emerging, Multifaceted Role of Mitophagy in Cancer and Cancer Therapeutics,” Seminars in Cancer Biology (2019).

[31] X. Cao, H. Wang, Z. Wang, et al., “In Vivo Imaging Reveals Mitophagy Independence in the Maintenance of Axonal Mitochondria during Normal Aging,” Aging Cell 16 (2017): 1180–1190.

[32] L. Uoselis, T. N. Nguyen, and M. Lazarou, “Mitochondrial Degradation: Mitophagy and beyond,” Molecular Cell 83 (2023): 3404–3420.

[33] T. N. Nguyen, B. S. Padman, and M. Lazarou, “Deciphering the Molecular Signals of Pink1/Parkin Mitophagy,” Trends in Cell Biology 26 (2016): 733–744.

[34] C. Gladkova, S. L. Maslen, J. M. Skehel, and D. Komander, “Mechanism of Parkin Activation by Pink1,” Nature 559 (2018): 410–414.

[35] T. Wauer, K. N. Swatek, J. L. Wagstaff, et al., “Ubiquitin Ser65 Phosphorylation Affects Ubiquitin Structure, Chain Assembly and Hydrolysis,” The EMBO Journal 34 (2015): 307–325.

[36] S. A. Sarraf, D. P. Sideris, N. Giagtzoglou, et al., “Pink1/Parkin Influences Cell Cycle by Sequestering Tbk1 at Damaged Mitochondria, Inhibiting Mitosis,” Cell Reports 29 (2019): 225–235.e5.

[37] P. Terešak, A. Lapao, N. Subic, et al., “Regulation of Prkn-Independent Mitophagy,” Autophagy (2021).

[38] R. Yu, T. Liu, S.-B. Jin, et al., “Mief1/2 Orchestrate Mitochondrial Dynamics Through Direct Engagement With both the Fission and Fusion Machineries,” BMC Biology 19 (2021): 229.

[39] J. Noone, D. J. O'Gorman, and H. C. Kenny, “Opa1 Regulation of Mitochondrial Dynamics in Skeletal and Cardiac Muscle,” Trends in Endocrinology & Metabolism 33 (2022): 710–721.

[40] I. Leong, “Metabolism: Drp1 Links Mitochondrial Dynamics to the Clock,” Nature Reviews Endocrinology 14 (2018): 624–624.

[41] T. Zhao, D. Niu, Y. Chen, and P. Fu, “The Role of Mitochondrial Quality Control Mechanisms in Chondrocyte Senescence,” Experimental Gerontology 188 (2024): 112379.

[42] D. Sebastián, M. Palacín, and A. Zorzano, “Mitochondrial Dynamics: Coupling Mitochondrial Fitness With Healthy Aging,” Trends in Molecular Medicine 23 (2017): 201–215.

[43] L. Pernas and L. Scorrano, “Mito-Morphosis: Mitochondrial Fusion, Fission, and Cristae Remodeling as Key Mediators of Cellular Function,” Annual Review of Physiology (2015).

[44] N. Preminger and M. Schuldiner, “Beyond Fission and Fusion—Diving Into the Mysteries of Mitochondrial Shape,” PLoS Biology 22 (2024): e3002671.

[45] R. Kowluru, “Modulation of Dynamic Mitochondria by Epigenetics in Diabetic Retinopathy,” Free Radical Biology and Medicine 128 (2018): S138–S139.

[46] C.-H. Yao, R. Wang, Y. Wang, et al., “Mitochondrial Fusion Supports Increased Oxidative Phosphorylation during Cell Proliferation,” Elife 8 (2019).

[47] K. L. H. Wu, C.-W. Wu, L.-W. Chen, et al., “Dysregulation of Mitochondrial Dynamics Mediated Aortic Perivascular Adipose Tissue-Associated Vascular Reactivity Impairment Under Excessive Fructose Intake,” Nutrition & Metabolism 21 (2024): 4.

[48] A. Mourier, E. Motori, T. Brandt, et al., “Mitofusin 2 Is Required to Maintain Mitochondrial Coenzyme Q Levels,” Journal of Cell Biology 208 (2015): 429–442.

[49] R. Quintana-Cabrera, I. Manjarrés-Raza, C. Vicente-Gutiérrez, et al., “Opa1 Relies on Cristae Preservation and Atp Synthase to Curtail Reactive Oxygen Species Accumulation in Mitochondria,” Redox Biology 41 (2021): 101944.

[50] Y. Peng, T. Zhao, S. Rong, et al., “Young Small Extracellular Vesicles Rejuvenate Replicative Senescence by Remodeling Drp1 Translocation-Mediated Mitochondrial Dynamics,” Journal of Nanobiotechnology 22 (2024): 543.

[51] N. U. Naresh and C. M. Haynes, “Signaling and Regulation of the Mitochondrial Unfolded Protein Response,” Cold Spring Harbor Perspectives in Biology 11 (2019): a033944.

[52] C. J. Fiorese, A. M. Schulz, Y.-F. Lin, et al., “The Transcription Factor Atf5 Mediates a Mammalian Mitochondrial Upr,” Current Biology 26 (2016): 2037–2043.

[53] J. R. Inigo and D. Chandra, “The Mitochondrial Unfolded Protein Response (Uprmt): Shielding Against Toxicity to Mitochondria in Cancer,” Journal of Hematology & Oncology 15 (2022): 98.

[54] F. Muñoz-Carvajal and M. Sanhueza, “The Mitochondrial Unfolded Protein Response: A Hinge Between Healthy and Pathological Aging,” Frontiers in Aging Neuroscience 12 (2020): 581849.

[55] A. M. Nargund, M. W. Pellegrino, C. J. Fiorese, et al., “Mitochondrial Import Efficiency of Atfs-1 Regulates Mitochondrial Upr Activation,” Science 337 (2012): 587–590.

[56] I. Pimenta de Castro, A. C. Costa, D. Lam, et al., “Genetic Analysis of Mitochondrial Protein Misfolding in Drosophila Melanogaster,” Cell Death and Differentiation 19 (2012): 1308–1316.

[57] E. D. Runkel, S. Liu, R. Baumeister, and E. Schulze, “Surveillance-Activated Defenses Block the Ros-Induced Mitochondrial Unfolded Protein Response,” PLOS Genetics 9 (2013): e1003346.

[58] M. A. Qureshi, C. M. Haynes, and M. W. Pellegrino, “The Mitochondrial Unfolded Protein Response: Signaling From the Powerhouse,” Journal of Biological Chemistry 292 (2017): 13500–13506.

[59] V. Sorrentino, K. J. Menzies, and J. Auwerx, “Repairing Mitochondrial Dysfunction in Disease,” Annual Review of Pharmacology and Toxicology 58 (2018): 353–389.

[60] B. F. Teske, M. E. Fusakio, D. Zhou, et al., “Chop Induces Activating Transcription Factor 5 (Atf5) to Trigger Apoptosis in Response to Perturbations in Protein Homeostasis,” Molecular Biology of the Cell 24 (2013): 2477–2490.

[61] Q. Zhou, W. Wang, J. Wu, et al., “Ubiquitin-Specific Protease 3 Attenuates Interleukin-1β-Mediated Chondrocyte Senescence by Deacetylating Forkhead Box O-3 Via Sirtuin-3,” Bioengineered 13, no. 2 (2022): 2017–2027.

[62] Y. Wang, W. He, W. Wei, et al., “Exenatide Attenuates Obesity-Induced Mitochondrial Dysfunction by Activating Sirt1 in Renal Tubular Cells,” Frontiers in Endocrinology 12 (2021): 622737.

[63] X. Lin, W. Ke, L. Qian, et al., “Cd38 Deficiency Protects Mice From High Fat Diet-Induced Nonalcoholic Fatty Liver Disease Through Activating Nad+/Sirtuins Signaling Pathways-Mediated Inhibition of Lipid Accumulation and Oxidative Stress in Hepatocytes,” International Journal of Biological Sciences 17, no. 15 (2021): 4305–4315.

[64] A. Saedan Kutin, A. J. Almzaiel, and A. Al-Badry, “Sirtuin 1 Expression Enhances the Inflammatory Response in Allergic Rhinitis Combined With Asthma,” Archives of Razi Institute 77, no. 6 (2022): 2385–2393.

[65] Z. Cheng, Z. Liu, C. Liu, et al., “Esculin Suppresses the Perk-Eif2α-Chop Pathway by Enhancing Sirt1 Expression in Oxidative Stress-Induced Rat Chondrocytes, Mitigating Osteoarthritis Progression in a Rat Model,” International Immunopharmacology 132 (2024): 112061.

[66] W. Voos and K. Pollecker, “The Mitochondrial Lon Protease: Novel Functions off the Beaten Track?,” Biomolecules 10 (2020): 253.

[67] N. Kunová, G. Ondrovičová, J. A. Bauer, et al., “The Role of Lon-Mediated Proteolysis in the Dynamics of Mitochondrial Nucleic Acid-Protein Complexes,” Scientific Reports 7, no. 1 (2017): 631.

[68] I. Mohammed, K. A. Schmitz, N. Schenck, et al., “Catalytic Cycling of Human Mitochondrial Lon Protease,” Structure 30 (2022): 1254–1268.e7.

[69] G. Pareek, R. E. Thomas, E. S. Vincow, et al., “Lon Protease Inactivation in Drosophila Causes Unfolded Protein Stress and Inhibition of Mitochondrial Translation,” Cell Death Discovery 4 (2018): 51.

[70] L. Zheng, L. Li, Z. Liu, et al., “Huangjing Yangji Decoction Ameliorates Skeletal Muscle Aging and Mitochondrial Dysfunction via Sirt1/Atf5-Mediated Mitochondrial Unfolded Protein Response,” Phytomedicine 148 (2025): 157432.

[71] N.-A. Gabriela, C.-G. Zeltzin Alejandra, Z. Cecilia, and S.-P. Alejandro, “A Look at Mercs as Upr<Sup>Mt</Sup>Regulatory Hubs in Age-Associated Heart Diseases,” The Journal of Cardiovascular Aging 5 (2025): 3.

[72] Y. Li, D. Huang, L. Jia, et al., “Lonp1 Links Mitochondria-Er Interaction to Regulate Heart Function,” Translated by Research 6 (2023): 0175.

[73] C. Ploumi, I. Daskalaki, and N. Tavernarakis, “Mitochondrial Biogenesis and Clearance: A Balancing Act,” The FEBS Journal (2016).

[74] J. Zhu, K. Z. Q. Wang, and C. T. Chu, “After the Banquet: Mitochondrial Biogenesis, Mitophagy, and Cell Survival,” Autophagy 9 (2013): 1663–1676.

[75] S. B. Vafai and V. K. Mootha, “Mitochondrial Disorders as Windows Into an Ancient Organelle,” Nature 491 (2012): 374–383.

[76] K. Hasegawa, T. Yasuda, C. Shiraishi, et al., “Promotion of Mitochondrial Biogenesis by Necdin Protects Neurons Against Mitochondrial Insults,” Nature Communications 7 (2016): 10943.

[77] A. Habara, C. Le, G. J. Murphy, et al., “Regulating Transcriptional Co-Activator Pgc-1α for the Treatment of Sickle Cell Disease,” Blood 132 (2018): 2358–2358.

[78] H. Wang, J. Su, M. Yu, et al., “Pgc-1α in Osteoarthritic Chondrocytes: From Mechanism to Target of Action,” Frontiers in Pharmacology 14 (2023): 1169019.

[79] B. Yu, L. Huo, Y. Liu, et al., “Pgc-1α Controls Skeletal Stem Cell Fate and Bone-Fat Balance in Osteoporosis and Skeletal Aging by Inducing Taz,” Cell Stem Cell 23 (2018): 193–209.e5.

[80] R. X. Santos, S. C. Correia, X. Zhu, et al., “Mitochondrial DNA Oxidative Damage and Repair in Aging and Alzheimer's Disease,” Antioxidants & Redox Signaling (2012).

[81] K. L. DeBalsi, K. E. Hoff, and W. C. Copeland, “Role of the Mitochondrial DNA Replication Machinery in Mitochondrial DNA Mutagenesis, Aging and Age-Related Diseases,” Ageing Research Reviews (2016).

[82] A. Kobayashi, K. Azuma, K. Ikeda, and S. Inoue, “Mechanisms Underlying the Regulation of Mitochondrial Respiratory Chain Complexes by Nuclear Steroid Receptors,” International Journal of Molecular Sciences 21 (2020): 6683.

[83] J. S. Riley and S. W. Tait, “Mitochondrial DNA in Inflammation and Immunity,” EMBO Reports 21 (2020).

[84] M. U. Kuk, Y. H. Lee, D. Kim, et al., “Sauchinone Ameliorates Senescence Through Reducing Mitochondrial Ros Production,” Antioxidants 14 (2025): 259.

[85] S. Kuzmiak-Glancy, B. Glancy, and M. W. Kay, “Ischemic Damage to every Segment of the Oxidative Phosphorylation Cascade Elevates Etc Driving Force and Ros Production in Cardiac Mitochondria,” American Journal of Physiology-Heart and Circulatory Physiology 323 (2022): H499–H512.

[86] Y. Tang, J. Wu, X. Sun, et al., “Cardiolipin Oxidized by Ros From Complex Ii Acts as a Target of Gasdermin D to Drive Mitochondrial Pore and Heart Dysfunction in Endotoxemia,” Cell Reports 43 (2024): 114237.

[87] C. Wiel, H. Lallet-Daher, D. Gitenay, et al., “Endoplasmic Reticulum Calcium Release Through Itpr2 Channels Leads to Mitochondrial Calcium Accumulation and Senescence,” Nature Communications 5 (2014): 3792.

[88] H. Rottenberg and J. B. Hoek, “The Path From Mitochondrial Ros to Aging Runs Through the Mitochondrial Permeability Transition Pore,” Aging Cell 16 (2017): 943–955.

[89] J. Goh, E. Wong, J. Soh, et al., “Targeting the Molecular & Cellular Pillars of Human Aging With Exercise,” The FEBS Journal (2021).

[90] A. Vujic, A. N. M. Koo, H. A. Prag, and T. Krieg, “Mitochondrial Redox and Tca Cycle Metabolite Signaling in the Heart,” Free Radical Biology and Medicine 166 (2021): 287–296.

[91] L. Yang, Z. Ruan, X. Lin, et al., “Nad+ Dependent Uprmt Activation Underlies Intestinal Aging Caused by Mitochondrial DNA Mutations,” Nature Communications 15, no. 1 (2024): 546.

[92] W. Zhang, M. Song, J. Qu, and G.-H. Liu, “Epigenetic Modifications in Cardiovascular Aging and Diseases,” Circulation Research 123, no. 7 (2018): 773–786.

[93] N. Kurhaluk, “Tricarboxylic Acid Cycle Intermediates and Individual Ageing,” Biomolecules 14 (2024): 260.

[94] A. A. Parkhitko, E. Filine, S. E. Mohr, et al., “Targeting Metabolic Pathways for Extension of Lifespan and Healthspan Across Multiple Species,” Ageing Research Reviews 64 (2020): 101188.

[95] Z. Zhang, C. He, Y. Gao, et al., “Α-Ketoglutarate Delays Age-Related Fertility Decline in Mammals,” Aging Cell 20, no. 2 (2021): e13291.

[96] B. Gyanwali, Z. X. Lim, J. Soh, et al., “Alpha-Ketoglutarate Dietary Supplementation to Improve Health in Humans,” Trends in Endocrinology & Metabolism (2021).

[97] R. M. Chin, X. Fu, M. Y. Pai, et al., “The Metabolite Α-Ketoglutarate Extends Lifespan by Inhibiting Atp Synthase and Tor,” Nature 510 (2014): 397–401.

[98] Y. Su, T. Wang, N. Wu, et al., “Alpha-Ketoglutarate Extends Drosophila Lifespan by Inhibiting Mtor and Activating Ampk,” Aging-US 11 (2019): 4183–4197.

[99] B. Zdzisińska, A. Żurek, and M. Kandefer-Szerszeń, “Alpha-Ketoglutarate as a Molecule With Pleiotropic Activity: Well-Known and Novel Possibilities of Therapeutic Use,” Archivum Immunologiae et Therapiae Experimentalis (2016).

[100] W. Chen, X. Yu, Y. Wu, et al., “The Sesame Complex Regulates Cell Senescence Through the Generation of Acetyl-Coa,” Nature Metabolism 3 (2021): 983–1000.

[101] A. Ronowska, A. Szutowicz, H. Bielarczyk, et al., “The Regulatory Effects of Acetyl-Coa Distribution in the Healthy and Diseased Brain,” Frontiers in Cellular Neuroscience 12 (2018): 169.

[102] I. Martínez-Reyes and N. S. Chandel, “Mitochondrial Tca Cycle Metabolites Control Physiology and Disease,” Nature Communications 11 (2020): 102.

[103] P. C. Bradshaw, “Acetyl-Coa Metabolism and Histone Acetylation in the Regulation of Aging and Lifespan,” Antioxidants 10 (2021): 572.

[104] R. Nativio, G. Donahue, A. Berson, et al., “Dysregulation of the Epigenetic Landscape of Normal Aging in Alzheimer's Disease,” Nature Neuroscience 21, no. 4 (2018): 497–505.

[105] S. Lv, Y. Zhang, Y. Lin, et al., “Apoe4 Exacerbates the Senescence of Hippocampal Neurons and Spatial Cognitive Impairment by Downregulating Acetyl-Coa Level,” Aging Cell 22 (2023): e13932.

[106] H. Massudi, R. Grant, N. Braidy, et al., “Age-Associated Changes in Oxidative Stress and Nad+ Metabolism in Human Tissue,” PLoS ONE 7 (2012): e42357.

[107] E. Verdin, “Nad+ in Aging, Metabolism, and Neurodegeneration,” Science 350 (2015): 1208–1213.

[108] C. Franceschi, P. Garagnani, G. Vitale, et al., “Inflammaging and ‘Garb-Aging’,” Trends in Endocrinology & Metabolism 28, no. 3 (2017): 199–212.

[109] M. Conte, M. Martucci, A. Chiariello, et al., “Mitochondria, Immunosenescence and Inflammaging: A Role for Mitokines?,” Seminars in Immunopathology 42 (2020): 607–617.

[110] G. Desdín-Micó, G. Soto-Heredero, J. F. Aranda, et al., “T Cells With Dysfunctional Mitochondria Induce Multimorbidity and Premature Senescence,” Science 368, no. 6497 (2020): 1371–1376.

[111] S. Marchi, E. Guilbaud, S. W. G. Tait, et al., “Mitochondrial Control of Inflammation,” Nature Reviews Immunology (2022).

[112] J. I. Jiménez-Loygorri, B. Villarejo-Zori, Á. Viedma-Poyatos, et al., “Mitophagy Curtails Cytosolic Mtdna-Dependent Activation of Cgas/Sting Inflammation during Aging,” Nature Communications 15, no. 1 (2024): 830.

[113] Y. Li, J. Cui, L. Liu, et al., “Mtdna Release Promotes Cgas-Sting Activation and Accelerated Aging of Postmitotic Muscle Cells,” Cell Death & Disease 15, no. 7 (2024): 523.

[114] S. Victorelli, H. Salmonowicz, J. Chapman, et al., “Apoptotic Stress Causes Mtdna Release during Senescence and Drives the Sasp,” Nature 622 (2023): 627–636.

[115] B. He, H. Yu, S. Liu, et al., “Mitochondrial Cristae Architecture Protects Against Mtdna Release and Inflammation,” Cell Reports 41 (2022): 111774.

[116] J. Kim, H.-S. Kim, and J. H. Chung, “Molecular Mechanisms of Mitochondrial DNA Release and Activation of the Cgas-Sting Pathway,” Experimental & Molecular Medicine 55, no. 3 (2023): 510–519.

[117] A. M. Casey, D. G. Ryan, H. A. Prag, et al., “Pro-Inflammatory Macrophages Produce Mitochondria-Derived Superoxide by Reverse Electron Transport at Complex I That Regulates Il-1β Release during Nlrp3 Inflammasome Activation,” Nature Metabolism 7 (2025): 493–507.

[118] A. K. Meyers and X. Zhu, “The Nlrp3 Inflammasome: Metabolic Regulation and Contribution to Inflammaging,” Cells 9 (2020): 1808.

[119] L. Soraci, M. E. Gambuzza, L. Biscetti, et al., “Toll-Like Receptors and Nlrp3 Inflammasome-Dependent Pathways in Parkinson's Disease: Mechanisms and Therapeutic Implications,” Journal of Neurology 270, no. 3 (2022): 1346–1360.

[120] E. Naddaf, T. K. O. Nguyen, and J. O. Watzlawik, “Nlrp3 Inflammasome Activation and Altered Mitophagy Are Key Pathways in Inclusion Body Myositis,” Journal of Cachexia, Sarcopenia and Muscle 16, no. 1 (2024): e13672.

[121] Y. Huang, C. Wang, H. Cui, et al., “Mitochondrial Dysfunction in Age-Related Sarcopenia: Mechanistic Insights, Diagnostic Advances, and Therapeutic Prospects,” Frontiers in Cell and Developmental Biology 13 (2025): 1590524.

[122] W. Li, W.-S. Jiang, Y.-R. Su, et al., “Pink1/Parkin-Mediated Mitophagy Inhibits Osteoblast Apoptosis Induced by Advanced Oxidation Protein Products,” Cell Death & Disease 14, no. 2 (2023): 88.

[123] X.-J. Chen, Y.-Y. Yang, and Z.-C. Pan, “The Inhibition of Pink1/Drp1-Mediated Mitophagy by Hyperglycemia Leads to Impaired Osteoblastogenesis in Diabetes,” Iscience 28, no. 1 (2024): 111519.

[124] Y. L. Chai, H. Xing, J. R. Chong, et al., “Mitochondrial Translocase of the Outer Membrane Alterations May Underlie Dysfunctional Oxidative Phosphorylation in Alzheimer's Disease,” Journal of Alzheimer's Disease 61, no. 2 (2018): 793–801.

[125] P. Qin, X. Chen, P. Ma, et al., “Mitochondrial DNA Copy Number and Alzheimer's Disease and Parkinson Disease,” Mitochondrion 83 (2025): 102032.

[126] D. B. Hier, S. Azizi, M. S. Thimgan, and D. C. Wunsch, “Tau Kinetics in Alzheimer's Disease,” Frontiers in Aging Neuroscience 14 (2022): 1055170.

[127] F. Rahmani, A. Kamalian, and M. H. Aarabi, “New Evidence Comes to Light: How Is Α -Synuclein Aggregation Related to Mitochondrial Protein Import in Parkinson's Disease?,” Movement Disorders 108, no. 31 (2016): 12937–12942.

[128] K. Y. Ma, M. R. Fokkens, F. Reggiori, et al., “Parkinson's Disease–Associated Vps35 Mutant Reduces Mitochondrial Membrane Potential and Impairs Pink1/Parkin-Mediated Mitophagy,” Translational Neurodegeneration 10 (2021): 19.

[129] K. Pircs, R. A. Barker, and J. Jakobsson, “Hunting out the Autophagic Problem in Huntington Disease,” Autophagy 18 (2022): 3031–3032.

[130] A. Dangoumau, S. Marouillat, R. Coelho, et al., “Dysregulations of Expression of Genes of the Ubiquitin/Sumo Pathways in an in Vitro Model of Amyotrophic Lateral Sclerosis Combining Oxidative Stress and Sod1 Gene Mutation,” International Journal of Molecular Sciences 22 (2021): 1796.

[131] A. Hahn, G. C. C. Hung, A. Ahier, et al., “Misregulation of Mitochondrial 6ma Promotes the Propagation of Mutant Mtdna and Causes Aging in C. elegans,” Cell Metabolism 36 (2024): 2528–2541.e11.

[132] F. Zhang, L. Zhang, G. Hu, et al., “Rectifying Mettl4-Mediated N6-Methyladenine Excess in Mitochondrial DNA Alleviates Heart Failure,” Circulation 150, no. 18 (2024): 1441–1458.

[133] S. Rao, N. Gautier, M. Woolard, et al., “Loss of Nicotinamide Nucleotide Transhydrogenase Promotes Redox Dependent Endothelial Activation in Atherosclerosis,” Physiology 38 (2023).

[134] C. Sakai, M. Ishida, K. Ueda, et al., “Abstract 10917: Dna Damage Promotes Atherosclerosis by Enhancing Inflammatory Responses via the DNA Sensing Cgas-Sting Pathway,” Circulation 144 (2021).

[135] Z. Hoseini, F. Sepahvand, B. Rashidi, et al., “Nlrp3 Inflammasome: Its Regulation and Involvement in Atherosclerosis,” Journal of Cellular Physiology (2017).

[136] M. Cree-Green, R. L. Scalzo, K. Harrall, et al., “Supplemental Oxygen Improvesin-Vivomitochondrial Oxidative Phosphorylation Flux in Sedentary Obese Adults With Type 2 Diabetes,” Diabetes 67 (2018): 1369–1379.

[137] Y. Zhang, X. Yu, M. Wang, et al., “Hyperoside From Z. Bungeanum Leaves Restores Insulin Secretion and Mitochondrial Function by Regulating Pancreatic Cellular Redox Status in Diabetic Mice,” Free Radical Biology and Medicine 162 (2020): 412–422.

[138] P. Marzuillo, “Understanding the Pathophysiological Mechanisms in the Pediatric Non-Alcoholic Fatty Liver Disease: The Role of Genetics,” World Journal of Hepatology 7 (2015): 1439.

[139] Y. Chouik, M. Di Filippo, S. Radenne, et al., “Combination of Heterozygous Apob Gene Mutation With Pnpla3 and Tm6sf2 Variants Promotes Steatotic Liver Disease, Cirrhosis and Hcc Development,” Liver International 44 (2024): 1474–1477.

[140] V. R. Kedlian, Y. Wang, T. Liu, et al., “Human Skeletal Muscle Aging Atlas,” Nature Aging 4 (2024): 727–744.

[141] N. T. Kamarulzaman and S. Makpol, “The Link Between Mitochondria and Sarcopenia,” Journal of Physiology and Biochemistry 81 (2025): 1–20.

[142] M. P. Murphy, H. Bayir, V. Belousov, et al., “Guidelines for Measuring Reactive Oxygen Species and Oxidative Damage in Cells and in Vivo,” Nature Metabolism 4 (2022): 651–662.

[143] S. Lourenço dos Santos, M. A. Baraibar, S. Lundberg, et al., “Oxidative Proteome Alterations during Skeletal Muscle Ageing,” Redox Biology 5 (2015): 267–274.

[144] M. Zicarelli, M. Musolino, M. Greco, et al., “#2747 Mots-C Levels and Sarcopenia Risk in Patients on Chronic Peritoneal Dialysis: A Pilot Study,” Nephrology Dialysis Transplantation 61, no. 2 (2025): 322.

[145] A. del Campo, I. Contreras-Hernández, M. Castro-Sepúlveda, et al., “Muscle Function Decline and Mitochondria Changes in Middle Age Precede Sarcopenia in Mice,” Aging-US 10 (2018): 34–55.

[146] M. Dong and A. D. Maturana, “Effects of Aging on Calcium Channels in Skeletal Muscle,” Frontiers in Molecular Biosciences 12 (2025): 1558456.

[147] D. Sharma, A. I. Larriera, P. E. Palacio-Mancheno, et al., “The Effects of Estrogen Deficiency on Cortical Bone Microporosity and Mineralization,” Bone 110 (2018): 1–10.

[148] L. Chen, X. Shi, J. Xie, et al., “Apelin-13 Induces Mitophagy in Bone Marrow Mesenchymal Stem Cells to Suppress Intracellular Oxidative Stress and Ameliorate Osteoporosis by Activation of Ampk Signaling Pathway,” Free Radical Biology and Medicine (2020).

[149] C. W. Bai, B. Tian, M. C. Zhang, et al., “Targeting Nampt-Opa1 for Treatment of Senile Osteoporosis,” Aging Cell (2024).

[150] Y. Qiao, D. Yi, D. A. Reed, et al., “A Novel Approach to Establishing a Temporomandibular Joint Fibrocartilage Cell Line,” Journal of Dental Sciences 17 (2022): 1378–1386.

[151] L. Pedrera, L. Prieto Clemente, A. Dahlhaus, et al., “Ferroptosis Triggers Mitochondrial Fragmentation via Drp1 Activation,” Cell Death & Disease 16 (2025): e14400.

[152] J. Suh, N.-K. Kim, W. Shim, et al., “Mitochondrial Fragmentation and Donut Formation Enhance Mitochondrial Secretion to Promote Osteogenesis,” Cell Metabolism 35 (2023): 345–360.e7.

[153] K. Palikaras, E. Lionaki, and N. Tavernarakis, “Mechanisms of Mitophagy in Cellular Homeostasis, Physiology and Pathology,” Nature Cell Biology 20 (2018): 1013–1022.

[154] M. Iguchi, M. Hiroi, H. Kanegae, and Y. Ohmori, “Costimulation of Murine Osteoblasts With Interferon-Γ and Tumor Necrosis Factor-Α Induces Apoptosis Through Downregulation of Bcl-2 and Release of Cytochrome C From Mitochondria,” Mediators of Inflammation 2018 (2018): 1–10.

[155] M. K. Jha and B. M. Morrison, “Glia-Neuron Energy Metabolism in Health and Diseases: New Insights Into the Role of Nervous System Metabolic Transporters,” Experimental Neurology 309 (2018): 23–31.

[156] Y. Zhang, H. Yang, D. Wei, et al., “Mitochondria-Targeted Nanoparticles in Treatment of Neurodegenerative Diseases,” Exploration 1 (2021): 20210115.

[157] A. Singh, R. Kukreti, L. Saso, and S. Kukreti, “Oxidative Stress: A Key Modulator in Neurodegenerative Diseases,” Molecules 24 (2019): 1583.

[158] P. R. Angelova and A. Y. Abramov, “Role of Mitochondrial Ros in the Brain: From Physiology to Neurodegeneration,” Translated by F. Lett., no. 1873–3468 (Electronic).

[159] O. Antico, P. W. Thompson, N. T. Hertz, et al., “Targeting Mitophagy in Neurodegenerative Diseases,” Nature Reviews Drug Discovery 24 (2025): 276–299.

[160] D. M. Wilson, M. R. Cookson, L. Van Den Bosch, et al., “Hallmarks of Neurodegenerative Diseases,” Cell 186, no. 4 (2023): 693–714.

[161] R. H. Swerdlow, “The Alzheimer's Disease Mitochondrial Cascade Hypothesis: A Current Overview,” Journal of Alzheimer's Disease 92 (2023): 751–768.

[162] S. J. Kish, C. Bergeron, A. Rajput, et al., “Brain Cytochrome Oxidase in Alzheimer's Disease,” Journal of Neurochemistry 59 (1992): 776–779.

[163] G. E. Gibson, J. P. Sheu Kf Fau-Blass, A. Blass Jp Fau-Baker, et al., “Reduced Activities of Thiamine-Dependent Enzymes in the Brains and Peripheral Tissues of Patients With Alzheimer's Disease,” Archives of Neurology 45, no. 8 (1988): 836–840.

[164] J. S. Beck, E. J. Mufson, and S. E. Counts, “Evidence for Mitochondrial Upr Gene Activation in Familial and Sporadic Alzheimer's Disease,” Current Alzheimer Research (2015).

[165] G. A.-O. Monzio Compagnoni, A. Di Fonzo, S. Corti, et al., “The Role of Mitochondria in Neurodegenerative Diseases: The Lesson From Alzheimer's Disease and Parkinson's Disease,” Molecular Neurobiology 57, no. 7 (2020): 2959–2980.

[166] V. Sorrentino, M. Romani, L. Mouchiroud, et al., “Enhancing Mitochondrial Proteostasis Reduces Amyloid-Β Proteotoxicity,” Nature 552 (2017): 187–193.

[167] W. Poewe, K. Seppi, C. M. Tanner, et al., “Parkinson Disease,” Nature Reviews Disease Primers 3, no. 1 (2017): 17013.

[168] B. R. Bloem, M. S. Okun, and C. Klein, “Parkinson's Disease,” The Lancet 397 (2021): 2284–2303.

[169] V. V. Goloborshcheva, V. G. Kucheryanu, N. A. Voronina, et al., “Synuclein Proteins in Mptp-Induced Death of Substantia Nigra Pars Compacta Dopaminergic Neurons,” Biomedicines 10 (2022): 2278.

[170] H. Li, B. Sun, Y. Huang, et al., “Gene Therapy of Yeast Ndi1 on Mitochondrial Complex I Dysfunction in Rotenone-Induced Parkinson's Disease Models in Vitro and Vivo,” Molecular Medicine 28, no. 1 (2022): 29.

[171] P. Ge, V. L. Dawson, and T. M. Dawson, “Pink1 and Parkin Mitochondrial Quality Control: A Source of Regional Vulnerability in Parkinson's Disease,” Molecular Neurodegeneration 15 (2020): 20.

[172] C. Dölle, I. Flønes, G. S. Nido, et al., “Defective Mitochondrial DNA Homeostasis in the Substantia Nigra in Parkinson Disease,” Nature Communications (2016).

[173] R. Di Maio, P. J. Barrett, E. K. Hoffman, et al., “Α-Synuclein Binds to Tom20 and Inhibits Mitochondrial Protein Import in Parkinson's Disease,” Science Translational Medicine 8 (2016): 342ra78.

[174] C. A. Ross and S. J. Tabrizi, “Huntington's Disease: From Molecular Pathogenesis to Clinical Treatment,” The Lancet Neurology 10, no. 1 (2011): 83–98.

[175] M. DiFiglia, K. O. Sapp E Fau-Chase, S. W. Chase Ko Fau-Davies, et al., “Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain,” Science 277, no. 5334 (1997): 1990–1993.

[176] S. Franco-Iborra, A. Plaza-Zabala, M. Montpeyo, et al., “Mutant Htt (Huntingtin) Impairs Mitophagy in a Cellular Model of Huntington Disease,” Autophagy (2020).

[177] J. Zhao, X. Wang, Z. Huo, et al., “The Impact of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis,” Cells 11, no. 13 (2022): 2049.

[178] H. Khan, R. Tundis, H. Ullah, et al., “Flavonoids Targeting Nrf2 in Neurodegenerative Disorders,” Food and Chemical Toxicology 146 (2020): 111817.

[179] N. A. Gude, K. M. Broughton, F. Firouzi, and M. A. Sussman, “Cardiac Ageing: Extrinsic and Intrinsic Factors in Cellular Renewal and Senescence,” Nature Reviews Cardiology 15 (2018): 523–542.

[180] I. Shimizu and T. Minamino, “Cellular Senescence in Cardiac Diseases,” Journal of Cardiology 74 (2019): 313–319.

[181] M. Abdellatif, P. P. Rainer, S. Sedej, and G. Kroemer, “Hallmarks of Cardiovascular Ageing,” Nature Reviews Cardiology 20 (2023): 754–777.

[182] A. Hinton, S. M. Claypool, K. Neikirk, et al., “Mitochondrial Structure and Function in Human Heart Failure,” Circulation Research 135 (2024): 372–396.

[183] C. Chen, J. Xie, Z. Chen, et al., “Role of Z-DNA Binding Protein 1 Sensing Mitochondrial Z-DNA and Triggering Necroptosis in Oxalate-Induced Acute Kidney Injury,” Journal of the American Society of Nephrology (2024).

[184] D. Jinfeng, C. Zijun, Z. Zijun, et al., “Mitochondrial Dysfunction Drives Zbp1-Mediated Panoptosis to Increase the Susceptibility of Heart Failure With Preserved Ejection Fraction-Associated Atrial Fibrillation,” Journal of Advanced Research (2025).

[185] Y. Lei, J. J. VanPortfliet, Y.-F. Chen, et al., “Cooperative Sensing of Mitochondrial DNA by Zbp1 and Cgas Promotes Cardiotoxicity,” Cell 186, no. 14 (2023): 3013–3032.

[186] R. Zhang, Y. Shen, L. Zhou, et al., “Short-Term Administration of Nicotinamide Mononucleotide Preserves Cardiac Mitochondrial Homeostasis and Prevents Heart Failure,” Journal of Molecular and Cellular Cardiology 112 (2017): 64–73.

[187] M. Yagi, Y. Do, H. Hirai, et al., “Improving Lysosomal Ferroptosis With Nmn Administration Protects Against Heart Failure,” Life Science Alliance 6 (2023): e202302116.

[188] G. D. Sloop, “Atherosclerosis–an Inflammatory Disease,” The New England Journal of Medicine (1999).

[189] B. G. Childs, M. Durik, D. J. Baker, and J. M. van Deursen, “Cellular Senescence in Aging and Age-Related Disease: From Mechanisms to Therapy,” Nature Medicine 21 (2015): 1424–1435.

[190] S. Zhang, B. Xia, B. Kalionis, et al., “The Role and Mechanism of Vascular Aging in Geriatric Vascular Diseases,” Aging and Disease 16, no. 4 (2024): 2237–2249.

[191] Y.-H. Youm, R. W. Grant, L. R. McCabe, et al., “Canonical Nlrp3 Inflammasome Links Systemic Low-Grade Inflammation to Functional Decline in Aging,” Cell Metabolism 18, no. 4 (2013): 519–532.

[192] Y. Peng, Y. Tao, L. Liu, et al., “Crosstalk Among Reactive Oxygen Species, Autophagy and Metabolism in Myocardial Ischemia and Reperfusion Stages,” Aging and Disease (2023).

[193] B. You, D. Yi, B. Wang, and H. Yan, “The Complex Bidirectional Relationship Between Aging and Atherosclerosis: Mechanistic Insights and Translational Opportunities,” Aging and Disease (2025).

[194] Y. Qiu, Y. Huang, M. Chen, et al., “Mitochondrial DNA in Nlrp3 Inflammasome Activation,” International Immunopharmacology 108 (2022): 108719.

[195] S. Horvath, “DNA Methylation Age of Human Tissues and Cell Types,” Genome Biology 14 (2013).

[196] U. Herbig, W. A. Jobling, B. P. C. Chen, et al., “Telomere Shortening Triggers Senescence of Human Cells Through a Pathway Involving Atm, P53, and P21(Cip1), but Not P16(Ink4a),” Molecular Cell 14, no. 4 (2004): 501–513.

[197] I. R. Baduini, J. E. Castro Vildosola, S. Kavehmoghaddam, et al., “Type 2 Diabetes Mellitus and Neurodegenerative Disorders: The Mitochondrial Connection,” Pharmacological Research 209 (2024): 107439.

[198] M. Longo, M. Meroni, E. Paolini, et al., “Mitochondrial Dynamics and Nonalcoholic Fatty Liver Disease (Nafld): New Perspectives for a Fairy-Tale Ending?,” Metabolism 117 (2021): 154708.

[199] C. Ridler, “Obesity: Inheritance via Mitochondria,” Nature Reviews Endocrinology 12 (2016): 497–497.

[200] C. Porter, D. N. Herndon, M. Chondronikola, et al., “Human and Mouse Brown Adipose Tissue Mitochondria Have Comparable Ucp1 Function,” Cell Metabolism 24 (2016): 246–255.

[201] J. M. Johnson, A. D. Peterlin, E. Balderas, et al., “Mitochondrial Phosphatidylethanolamine Modulates Ucp1 to Promote Brown Adipose Thermogenesis,” Science Advances 9 (2023): eade7864.

[202] P. V. McTavish and D. M. Mutch, “Omega-3 Fatty Acid Regulation of Lipoprotein Lipase and Fat/Cd36 and Its Impact on White Adipose Tissue Lipid Uptake,” Lipids in Health and Disease 23 (2024): 386.

[203] S.-B. Jung, M. J. Choi, D. Ryu, et al., “Reduced Oxidative Capacity in Macrophages Results in Systemic Insulin Resistance,” Nature Communications 9, no. 1 (2018): 1551.

[204] T. Matsuzawa, M. Morita, A. Shimane, et al., “Heparan Sulfate Promotes Differentiation of White Adipocytes to Maintain Insulin Sensitivity and Glucose Homeostasis,” Journal of Biological Chemistry 297 (2021): 101006.

[205] J. Y. Kim, J. Lee, S. G. Kim, and N. H. Kim, “Beta-Cell Function, Insulin Sensitivity, and Metabolic Characteristics in Young-Onset Type 2 Diabetes Mellitus: Findings From Anam Diabetes Observational Study,” Diabetes & Metabolism Journal 49 (2025): 1287–1297.

[206] S. Das, A. Mukhuty, G. P. Mullen, and M. C. Rudolph, “Adipocyte Mitochondria: Deciphering Energetic Functions Across Fat Depots in Obesity and Type 2 Diabetes,” International Journal of Molecular Sciences 25 (2024): 6681.

[207] N. Rachdaoui, “Insulin: The Friend and the Foe in the Development of Type 2 Diabetes Mellitus,” International Journal of Molecular Sciences 21 (2020): 1770.

[208] Y. Lu, J. Xu, Y. Li, et al., “Drak2 Suppresses Autophagy by Phosphorylating Ulk1 at Ser 56 to Diminish Pancreatic Β Cell Function Upon Overnutrition,” Science Translational Medicine 16, no. 733 (2024): eade8647.

[209] K. K. Bence and M. J. Birnbaum, “Metabolic Drivers of Non-Alcoholic Fatty Liver Disease,” Molecular Metabolism (2020).

[210] R. Loomba, S. L. Friedman, and G. I. Shulman, “Mechanisms and Disease Consequences of Nonalcoholic Fatty Liver Disease,” Cell 184 (2021): 2537–2564.

[211] J. Trebicka and R. Schierwagen, “Hepatic Mitochondrial Dysfunction in Nonalcoholic Steatohepatitis: Read-out or Reason?,” Hepatology 63 (2016): 1729–1732.

[212] R. Harjumäki, C. S. Pridgeon, and M. Ingelman-Sundberg, “Cyp2e1 in Alcoholic and Non-Alcoholic Liver Injury. Roles of Ros, Reactive Intermediates and Lipid Overload,” International Journal of Molecular Sciences 22 (2021): 8221.

[213] Y. Li, J. Xu, Y. Lu, et al., “Drak2 Aggravates Nonalcoholic Fatty Liver Disease Progression Through Srsf6-Associated Rna Alternative Splicing,” Cell Metabolism 33 (2021): 2004–2020.e9.

[214] Z. Bai, W. Yin, R. Liu, et al., “Prdx1 Cys52ser Variant Alleviates Nonalcoholic Steatohepatitis by Reducing Inflammation in Mice,” Molecular Metabolism 76 (2023): 101789.

[215] G. F. Kelso, C. M. Porteous, C. V. Coulter, et al., “Selective Targeting of a Redox-Active Ubiquinone to Mitochondria Within Cells: Antioxidant and Antiapoptotic Properties,” Journal of Biological Chemistry 276 (2001): 4588–4596.

[216] E. J. Gane, F. Weilert, D. W. Orr, et al., “The Mitochondria-Targeted Anti-Oxidant Mitoquinone Decreases Liver Damage in a Phase Ii Study of Hepatitis C Patients,” Liver International 30 (2010): 1019–1026.

[217] B. J. Snow, F. L. Rolfe, M. M. Lockhart, et al., “A Double-Blind, Placebo-Controlled Study to Assess the Mitochondria-Targeted Antioxidant Mitoq as a Disease-Modifying Therapy in Parkinson's Disease,” Movement Disorders 25, no. 11 (2010): 1670–1674.

[218] V. P. Skulachev, V. N. Anisimov, Y. N. Antonenko, et al., “An Attempt to Prevent Senescence: A Mitochondrial Approach,” Biochimica et Biophysica Acta 1787 (2009): 437–461, (BBA)—Bioenergetics.

[219] V. P. Skulachev, Y. N. Antonenko, D. A. Cherepanov, et al., “Prevention of Cardiolipin Oxidation and Fatty Acid Cycling as Two Antioxidant Mechanisms of Cationic Derivatives of Plastoquinone (Skqs),” Biochimica et Biophysica Acta (BBA)—Bioenergetics 1797 (2010): 878–889.

[220] V. V. Brzheskiy, E. L. Efimova, T. N. Vorontsova, et al., “Results of a Multicenter, Randomized, Double-Masked, Placebo-Controlled Clinical Study of the Efficacy and Safety of Visomitin Eye Drops in Patients With Dry Eye Syndrome,” Advances in Therapy 32 (2015): 1263–1279.

[221] H. N. Sabbah, R. C. Gupta, S. Kohli, et al., “Chronic Therapy With Elamipretide (Mtp-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure,” Circulation: Heart Failure 9, no. 2 (2016): e002206.

[222] M. T. Sweetwyne, J. W. Pippin, D. G. Eng, et al., “The Mitochondrial-Targeted Peptide, Ss-31, Improves Glomerular Architecture in Mice of Advanced Age,” Kidney International 91 (2017): 1126–1145.

[223] M. D. Campbell, J. Duan, A. T. Samuelson, et al., “Improving Mitochondrial Function With Ss-31 Reverses Age-Related Redox Stress and Improves Exercise Tolerance in Aged Mice,” Free Radical Biology and Medicine (2018).

[224] J. D. Chavez, X. Tang, M. D. Campbell, et al., “Mitochondrial Protein Interaction Landscape of Ss-31,” Proceedings of the National Academy of Sciences of the United States of America 117 (2020): 15363–15373.

[225] I. Rutkai, A. Seman, P. Chandra, et al., “The Beneficial Effects of Ss-31 on Aging Mice Cerebral Microvasculature,” Physiology 38 (2023).

[226] A. E. Dikalova, A. T. Bikineyeva, K. Budzyn, et al., “Therapeutic Targeting of Mitochondrial Superoxide in Hypertension,” Circulation Research 107 (2010): 106–116.

[227] J. Trnka, F. H. Blaikie, R. A. J. Smith, and M. P. Murphy, “A Mitochondria-Targeted Nitroxide Is Reduced to Its Hydroxylamine by Ubiquinol in Mitochondria,” Free Radical Biology and Medicine 44, no. 7 (2008): 1406–1419.

[228] J. Zheng, W. Zhang, J. Ito, et al., “N-Acetyl-L-Cysteine Averts Ferroptosis by Fostering Glutathione Peroxidase 4,” Cell Chemical Biology 32 (2025): 767–775.e5.

[229] S. Maurer, M. Fuchs, R. E. Brenner, and J. Riegger, “Glutathione Has Cell Protective and Anti-Catabolic Effects in Articular Cartilage Without Impairing the Chondroanabolic Phenotype,” Heliyon 10, no. 22 (2024): e40368.

[230] T. Kabir, H. Yoshiba, A. Z. Agista, et al., “Protective Effects of Gnetin C From Melinjo Seed Extract Against High-Fat Diet-Induced Hepatic Steatosis and Liver Fibrosis in Nafld Mice Model,” Nutrients 15 (2023): 3888.

[231] W.-J. Fang, X.-M. Li, X.-K. Zhou, and Y. Xiong, “Resveratrol Improves Diabetic Cardiomyopathy by Preventing Asymmetric Dimethylarginine-Caused Peroxisome Proliferator-Activated Receptor-Γ Coactivator-1α Acetylation,” European Journal of Pharmacology 936 (2022): 175342.

[232] M. Ye, H. Wu, and S. Li, “Resveratrol Alleviates Oxygen/Glucose Deprivation/Reoxygenation‑Induced Neuronal Damage Through Induction of Mitophagy,” Molecular Medicine Reports 23 (2020): 73.

[233] A. S. Martin, D. M. Abraham, K. A. Hershberger, et al., “Nicotinamide Mononucleotide Requires Sirt3 to Improve Cardiac Function and Bioenergetics in a Friedreich's Ataxia Cardiomyopathy Model,” JCI Insight 2 (2017): e93885.

[234] S. M. Nadtochiy and P. S. Brookes, “Direct Stimulation of Glycolysis Accounts for Cellular Metabolic Benefits of the Nad + Precursor Nicotinamide Mononucleotide (Nmn),” Free Radical Biology and Medicine (2017).

[235] N. Klimova, A. Fearnow, A. Long, and T. Kristian, “Nad+ Precursor Modulates Post-Ischemic Mitochondrial Fragmentation and Reactive Oxygen Species Generation via Sirt3 Dependent Mechanisms,” Experimental Neurology (2019).

[236] T. Korolenko, N. Dubrovina, M. Ovsyukova, et al., “Treatment With Autophagy Inducer Trehalose Alleviates Memory and Behavioral Impairments and Neuroinflammatory Brain Processes in Db/Db Mice,” Cells 10 (2021): 2557.

[237] A. Stachowicz, A. Wiśniewska, K. Kuś, et al., “The Influence of Trehalose on Atherosclerosis and Hepatic Steatosis in Apolipoprotein E Knockout Mice,” International Journal of Molecular Sciences 20 (2019): 1552.

[238] D. Ryu, L. Mouchiroud, P. A. Andreux, et al., “Urolithin a Induces Mitophagy and Prolongs Lifespan in C. Elegans and Increases Muscle Function in Rodents,” Nature Medicine 22 (2016): 879–888.

[239] D. P. W. Jayatunga, E. Hone, H. Khaira, et al., “Therapeutic Potential of Mitophagy-Inducing Microflora Metabolite, Urolithin a for Alzheimer's Disease,” Nutrients 13 (2021): 3744.

[240] C. Duan, Y. Zhao, Y. Xiao, et al., “Lithium With Environmentally Relevant Concentrations Interferes With Mitochondrial Function, Antioxidant Response, and Autophagy Processes in Daphnia Magna, Leading to Changes in Life-History Traits and Behavior,” Journal of Hazardous Materials 488 (2025): 137420.

[241] P.-H. Chen, T.-W. Lee, S.-H. Liu, et al., “Lithium Downregulates Phosphorylated Acetyl‑Coa Carboxylase 2 and Attenuates Mitochondrial Fatty Acid Utilization and Oxidative Stress in Cardiomyocytes,” Experimental and Therapeutic Medicine 27, no. 4 (2024): 126.

[242] A. T. Dinkova-Kostova, J. W. Fahey, R. V. Kostov, and T. W. Kensler, “Keap1 and Done? Targeting the Nrf2 Pathway With Sulforaphane,” Trends in Food Science & Technology 69, no. Pt B (2017): 257–269.

[243] K. Boengler, M. Kosiol, M. Mayr, et al., “Mitochondria and Ageing: Role in Heart, Skeletal Muscle and Adipose Tissue,” Journal of Cachexia, Sarcopenia and Muscle 8, no. 3 (2017): 349–369.

[244] M. A. J. Smits, B. V. Schomakers, M. van Weeghel, et al., “Human Ovarian Aging Is Characterized by Oxidative Damage and Mitochondrial Dysfunction,” Human Reproduction 38 (2023): 2208–2220.

[245] L. P. Diniz, A. P. B. Araujo, C. F. Carvalho, et al., “Accumulation of Damaged Mitochondria in Aging Astrocytes due to Mitophagy Dysfunction: Implications for Susceptibility to Mitochondrial Stress,” Biochimica et Biophysica Acta 1870 (2024): 167470, (BBA)—Molecular Basis of Disease.

[246] J. W. Guarnieri, T. Lie, Y. E. S. Albrecht, et al., “Mitochondrial Antioxidants Abate Sars-Cov-2 Pathology in Mice,” Proceedings of the National Academy of Sciences of the United States of America 121 (2024):.

[247] E. V. Stelmashook, N. K. Isaev, E. E. Genrikhs, and S. V. Novikova, “Mitochondria-Targeted Antioxidants as Potential Therapy for the Treatment of Traumatic Brain Injury,” Antioxidants 8, no. 5 (2019): 124.

[248] J. Williamson, C. M. Hughes, J. N. Cobley, and G. W. Davison, “The Mitochondria-Targeted Antioxidant Mitoq, Attenuates Exercise-Induced Mitochondrial DNA Damage,” Redox Biology 36 (2020): 101673.

[249] V. Peugnet, M. Chwastyniak, P. Mulder, et al., “Mitochondrial-Targeted Therapies Require Mitophagy to Prevent Oxidative Stress Induced by Sod2 Inactivation in Hypertrophied Cardiomyocytes,” Antioxidants 11, no. 4 (2022): 723.

[250] N. A. Muraleva, O. S. Kozhevnikova, A. Z. Fursova, and N. G. Kolosova, “Suppression of Amd-Like Pathology by Mitochondria-Targeted Antioxidant Skq1 Is Associated With a Decrease in the Accumulation of Amyloid Β and in Mtor Activity,” Antioxidants 8, no. 6 (2019): 177.

[251] S. Koka, Z. Powers, and K. Boini, “Skq1 Improves Trimethylamine-N-Oxide-Induced Endothelial Dysfunction by Attenuating Oxidative Stress and Restoring Junctional Proteins,” Physiology 38 (2023): 101–112.

[252] M. C. D. S. Tenório, N. G. Graciliano, F. A. Moura, et al., “N-Acetylcysteine (Nac): Impacts on Human Health,” Antioxidants 10, no. 6 (2021): 967.

[253] P. Parra-Flores, J. A. Riquelme, P. Valenzuela-Bustamante, et al., “The Association of Ascorbic Acid, Deferoxamine and N-Acetylcysteine Improves Cardiac Fibroblast Viability and Cellular Function Associated With Tissue Repair Damaged by Simulated Ischemia/Reperfusion,” Antioxidants 8, no. 12 (2019): 614.

[254] J. Riegger, H. Joos, H. G. Palm, et al., “Antioxidative Therapy in an Ex Vivo Human Cartilage Trauma-Model: Attenuation of Trauma-Induced Cell Loss and Ecm-Destructive Enzymes by N-Acetyl Cysteine,” Osteoarthritis and Cartilage 24 (2016): 2171–2180.

[255] S. Tangtrongsup and J. D. Kisiday, “Modulating the Oxidative Environment during Mesenchymal Stem Cells Chondrogenesis With Serum Increases Collagen Accumulation in Agarose Culture,” Journal of Orthopaedic Research (2017).

[256] E. Stefaniak, B. Cui, K. Sun, et al., “Therapeutic Peptide Ss-31 Modulates Membrane Binding and Aggregation of Alpha-Synuclein and Restores Impaired Mitochondrial Function,” bioRxiv—Biochemistry (2024).

[257] K. Fukui, F. You, Y. Kato, et al., “A Blended Vitamin Supplement Improves Spatial Cognitive and Short-Term Memory in Aged Mice,” International Journal of Molecular Sciences 25 (2024): 2804.

[258] Y. Olmos, F. J. Sánchez-Gómez, B. Wild, et al., “Sirt1 Regulation of Antioxidant Genes Is Dependent on the Formation of a Foxo3a/Pgc-1α Complex,” Antioxidants & Redox Signaling 19 (2013): 1507–1521.

[259] D. Ran, D. Zhou, G. Liu, et al., “Reactive Oxygen Species Control Osteoblast Apoptosis Through Sirt1/Pgc-1α/P53lys382 Signaling, Mediating the Onset of Cd-Induced Osteoporosis,” Journal of Agricultural and Food Chemistry 71, no. 15 (2023): 5991–6002.

[260] K. B. Koronowski, N. Khoury, I. Saul, et al., “Neuronal Sirt1 (Silent Information Regulator 2 Homologue 1) Regulates Glycolysis and Mediates Resveratrol-Induced Ischemic Tolerance,” Stroke; A Journal of Cerebral Circulation 48, no. 11 (2017): 3117–3125.

[261] E. Martino, A. Balestrieri, C. Anastasio, et al., “Sirt3 Modulates Endothelial Mitochondrial Redox State during Insulin Resistance,” Antioxidants 11 (2022): 1611.

[262] T. Nespital, B. Neuhaus, A. Mesaros, et al., “Lithium Can Mildly Increase Health during Ageing but Not Lifespan in Mice,” Aging Cell 20 (2021).

[263] P. Rusmini, K. Cortese, V. Crippa, et al., “Trehalose Induces Autophagy via Lysosomal-Mediated Tfeb Activation in Models of Motoneuron Degeneration,” Autophagy (2018).

[264] C. Li, Z. Zhang, C. Luo, et al., “A Mitochondria-Targeted Nanomedicine for Myocardial Ischemia/Reperfusion Injury With Synergistic Antioxidant and Anti-Inflammatory Properties,” Journal of Nanobiotechnology 23, no. 1 (2025): 705.

[265] B. Castejon-Vega, M. D. Cordero, and A. Sanz, “How the Disruption of Mitochondrial Redox Signalling Contributes to Ageing,” Antioxidants 12 (2023): 831.

[266] V. Latapiat, M. Saez, I. Pedroso, and A. J. M. Martin, “Unraveling Patient Heterogeneity in Complex Diseases Through Individualized Co-Expression Networks: A Perspective,” Frontiers in Genetics 14 (2023): 1209416.

[267] A. Bitto, “Mitochondrial Transplants to Treat Mitochondrial Dysfunction,” Nature Metabolism 6 (2024): 1846–1847.

[268] M. P. Murphy, “How Mitochondria Produce Reactive Oxygen Species,” Biochemical Journal 417, no. 1 (2008): 1–13.

[269] S. Miwa and M. D. Brand, “Mitochondrial Matrix Reactive Oxygen Species Production Is Very Sensitive to Mild Uncoupling,” Biochemical Society Transactions 31 (2003): 1300–1301.

[270] J. Liu, D. W. Killilea, and B. N. Ames, “Age-Associated Mitochondrial Oxidative Decay: Improvement of Carnitine Acetyltransferase Substrate-Binding Affinity and Activity in Brain by Feeding Old Rats Acetyl-L- Carnitine and/or R-Alpha -Lipoic Acid,” in Proceedings of the National Academy of Sciences of the United States of America (2002).

[271] F. E. Oflaz, Z. Koshenov, M. Hirtl, et al., “Synergy of Uncoupling Proteins (1 and 2) With Mitochondrial Ca2+ Uptake Machinery Potentiate Mitochondrial Uncoupling,” Cell Calcium 112 (2023): 102736.

[272] A. Gagelin, C. Largeau, S. Masscheleyn, et al., “Molecular Determinants of Inhibition of Ucp1-Mediated Respiratory Uncoupling,” Nature Communications 14 (2023): 2594.

[273] X. Lin, H. Chen, and S. Qu, “211-Or: Chemerin Affects Mitochondrial Function by Modulating Pparγ/Pgc-1α/Ucp2 Signaling Pathway to Promote Metabolic Dysfunction-Associated Fatty Liver Disease,” Diabetes 74 (2025): e70657.

[274] R. Inoue, J. U. N. Shirakawa, Y. U. Togashi, and Y. Terauchi, “2161-P: Overexpression of Ucp2 in Pancreatic Beta Cells Caused Impaired Insulin Secretion Through Mitochondrial Dysfunction and Aldolase B Expression,” Diabetes (2019).

[275] Y. Takeda and P. Dai, “Chronic Fatty Acid Depletion Induces Uncoupling Protein 1 (Ucp1) Expression to Coordinate Mitochondrial Inducible Proton Leak in a Human-Brown-Adipocyte Model,” Cells 11 (2022): 2038.

[276] I. Bechmann, S. Diano, C. H. Warden, et al., “Brain Mitochondrial Uncoupling Protein 2 (Ucp2): A Protective Stress Signal in Neuronal Injury,” Biochemical Pharmacology 64 (2002): 363–367.

[277] M. Zhang, L. Wang, D. Wen, et al., “Neuroprotection of Retinal Cells by Caffeic Acid Phenylethyl Ester(Cape) Is Mediated by Mitochondrial Uncoupling Protein Ucp2,” Neurochemistry international 151 (2021): 105214.

[278] M. Ulgherait, A. Chen, S. F. McAllister, et al., “Circadian Regulation of Mitochondrial Uncoupling and Lifespan,” Nature Communications 11 (2020): 1927.

[279] A. Stachowicz, A. Wiśniewska, K. Czepiel, et al., “Mitochondria-Targeted Hydrogen Sulfide Donor Reduces Atherogenesis by Changing Macrophage Phenotypes and Increasing Ucp1 Expression in Vascular Smooth Muscle Cells,” Biomedicine & Pharmacotherapy 180 (2024): 117527.

[280] K. Hong, J. Wang, X. Kang, et al., “Ferulic Acid and Protocatechuic Acid Alleviate Atherosclerosis by Promoting Ucp1 Expression to Inhibit the Nlrp3-Il-1β Signaling Pathway,” Food & Function (2025).

[281] J. Gruber, S. Fong, C.-B. Chen, et al., “Mitochondria-Targeted Antioxidants and Metabolic Modulators as Pharmacological Interventions to Slow Ageing,” Biotechnology Advances 31, no. 5 (2013): 563–592.

[282] V. P. Skulachev, “A Biochemical Approach to the Problem of Aging: “Megaproject” on Membrane-Penetrating Ions. The First Results and Prospects,” Biochemistry (Moscow) 72, no. 12 (2007): 1385–1396.

[283] M. H. Barros, B. Bandy, E. B. Tahara, and A. J. Kowaltowski, “Higher Respiratory Activity Decreases Mitochondrial Reactive Oxygen Release and Increases Life Span in Saccharomyces Cerevisiae,” Journal of Biological Chemistry (2021).

[284] V. I. Padalko, “Uncoupler of Oxidative Phosphorylation Prolongs the Lifespan of Drosophila,” Biochemistry (Moscow) 70, no. 9 (2005): 986–989.

[285] C. C. Caldeira da Silva, F. M. Cerqueira, L. F. Barbosa, et al., “Mild Mitochondrial Uncoupling in Mice Affects Energy Metabolism, Redox Balance and Longevity,” Aging Cell 7 (2008): 552–560.

[286] W.-F. Li, Y. Zeng, Y.-D. Zhang, et al., “O304 Is a Mitochondrial Uncoupler Which Extends C. Elegans Lifespan and Induces Vasorelaxation of Rat Mesenteric Arteries,” Chemico-biological interactions 421 (2025): 111788.

[287] O. M. Strilbytska, U. Semaniuk, I. Yurkevych, et al., “2,4-Dinitrophenol Is Toxic on a Low Caloric Diet but Extends Lifespan of Drosophila Melanogaster on Nutrient-Rich Diets Without an Impact on Metabolism,” Biogerontology 26, no. 1 (2024): 27.

[288] P.-H. Lou, B. S. Hansen, P. H. Olsen, et al., “Mitochondrial Uncouplers With an Extraordinary Dynamic Range,” Biochemical Journal 407 (2007): 129–140.

[289] F. M. Cunha, C. C. Caldeira da Silva, F. M. Cerqueira, and A. J. Kowaltowski, “Mild Mitochondrial Uncoupling as a Therapeutic Strategy,” Current Drug Targets 12, no. 6 (2011): 783–789.

[290] J.-L. Gao, J. Zhao, H.-B. Zhu, et al., “Characterizations of Mitochondrial Uncoupling Induced by Chemical Mitochondrial Uncouplers in Cardiomyocytes,” Free Radical Biology and Medicine 124 (2018): 288–298.

[291] J. E. Quinlan, J. M. Salamoun, C. J. Garcia, et al., “Unsymmetric Hydroxylamine and Hydrazine Bam15 Derivatives as Potent Mitochondrial Uncouplers,” Bioorganic & Medicinal Chemistry (2024).

[292] J. Gruber, S. Fong, C.-B. Chen, et al., “Mitochondria-Targeted Antioxidants and Metabolic Modulators as Pharmacological Interventions to Slow Ageing,” Biotechnology Advances (2012).

[293] P. Patyal, G. Azhar, A. Verma, et al., “Mitochondrial Dynamics in Aging Heart,” Biomedicines 13 (2025): 2603.

[294] J. Gao, L. Wang, J. Liu, et al., “Abnormalities of Mitochondrial Dynamics in Neurodegenerative Diseases,” Antioxidants 6 (2017): 25.

[295] K. Panchal and A. K. Tiwari, “Mitochondrial Dynamics, a Key Executioner in Neurodegenerative Diseases,” Mitochondrion 47 (2019): 151–173.

[296] E. A. Bordt, N. Zhang, J. Waddell, and B. M. Polster, “The Non-Specific Drp1 Inhibitor Mdivi-1 Has Modest Biochemical Antioxidant Activity,” Antioxidants 11, no. 3 (2022): 450.

[297] C. Duan, L. Wang, J. Zhang, et al., “Mdivi-1 Attenuates Oxidative Stress and Exerts Vascular Protection in Ischemic/Hypoxic Injury by a Mechanism Independent of Drp1 Gtpase Activity,” Redox Biology 37 (2020): 101706.

[298] L. Zhan, Z. Lu, X. Zhu, et al., “Hypoxic Preconditioning Attenuates Necroptotic Neuronal Death Induced by Global Cerebral Ischemia via Drp1-Dependent Signaling Pathway Mediated by Camkiiα Inactivation in Adult Rats,” The FASEB Journal 33, no. 1 (2018): 1313–1329.

[299] A. Ruiz, T. Quintela-López, M. V. Sánchez-Gómez, et al., “Mitochondrial Division Inhibitor 1 Disrupts Oligodendrocyte Ca2+ Homeostasis and Mitochondrial Function,” Glia 68 (2020): 1743–1756.

[300] W. Dai, G. Wang, J. Chwa, et al., “Mitochondrial Division Inhibitor (Mdivi-1) Decreases Oxidative Metabolism in Cancer,” British Journal of Cancer 122 (2020): 1288–1297.

[301] Y. Chen, C. Yang, M. Zou, et al., “Inhibiting Mitochondrial Inflammation Through Drp1/Hk1/Nlrp3 Pathway: A Mechanism of Alpinetin Attenuated Aging-Associated Cognitive Impairment,” Phytotherapy Research 37 (2023): 2454–2471.

[302] Y. Guo, H. Zhang, C. Yan, et al., “Small Molecule Agonist of Mitochondrial Fusion Repairs Mitochondrial Dysfunction,” Nature Chemical Biology 19 (2023): 530–530.

[303] S. Z. Liu, Y. A. Chiao, P. S. Rabinovitch, and D. J. Marcinek, “Mitochondrial Targeted Interventions for Aging,” Cold Spring Harbor Perspectives in Medicine 14, no. 3 (2024): a041199.

[304] A. Zhang, Y. Pan, H. Wang, et al., “Excessive Processing and Acetylation of Opa1 Aggravate Age-Related Hearing Loss via the Dysregulation of Mitochondrial Dynamics,” Aging Cell 23, no. 4 (2024): e14091.

[305] A. Picca, R. Calvani, M. Lorenzi, et al., “Mitochondrial Dynamics Signaling Is Shifted Toward Fusion in Muscles of Very Old Hip-Fractured Patients: Results From the Sarcopenia in Hip Fracture (Shift) Exploratory Study,” Experimental Gerontology 96 (2017): 63–67.

[306] T.-W. Lee, H.-W. Liu, Y.-F. Lin, et al., “Histone Deacetylase Inhibition Improves Metabolism and Mitochondrial Dynamics: A Potential Novel Therapeutic Strategy for Sarcopenia Coexisting With Diabetes Mellitus,” Medical Hypotheses (2021).

[307] Y. Pang, M. Qin, P. Hu, et al., “Resveratrol Protects Retinal Ganglion Cells Against Ischemia Induced Damage by Increasing Opa1 Expression,” International Journal of Molecular Medicine 46, no. 5 (2020): 1707–1720.

[308] B. Banoth and S. L. Cassel, “Mitochondria in Innate Immune Signaling,” Translational Research 202 (2018): 52–68.

[309] L. E. Newman and G. S. Shadel, “Mitochondrial DNA Release in Innate Immune Signaling,” Annual Review of Biochemistry 92 (2023): 299–332.

[310] L. Wang, X. Zhang, X. Huang, et al., “Homoplantaginin Alleviates High Glucose-Induced Vascular Endothelial Senescence by Inhibiting Mtdna-Cgas-Sting Pathway via Blunting Drp1-Mitochondrial Fission-Vdac1 Axis,” The FASEB Journal 38 (2024): e70127.

[311] S. T. Chen, W. W. Shi, F. Ran, et al., “The Activation of Cgas-Sting Pathway Causes Abnormal Uterine Receptivity in Aged Mice,” Aging Cell 23 (2024).

[312] L. Wang, Z. Zhang, H. Zhang, et al., “The Effects of Cgas-Sting Inhibition in Liver Disease, Kidney Disease, and Cellular Senescence,” Frontiers in Immunology 15 (2024): 1346446.

[313] J. Shao, Y. Meng, K. Yuan, et al., “Ru.521 Mitigates Subarachnoid Hemorrhage-Induced Brain Injury via Regulating Microglial Polarization and Neuroinflammation Mediated by the Cgas/Sting/Nf-Κb Pathway,” Cell Communication and Signaling 21 (2023): 264.

[314] X. Xie, G. Ma, X. Li, et al., “Activation of Innate Immune Cgas-Sting Pathway Contributes to Alzheimer's Pathogenesis in 5×Fad Mice,” Nature Aging 3 (2023): 202–212.

[315] R. Dhapola, M. Paidlewar, S. Kumari, et al., “Cgas-Sting and Neurodegenerative Diseases: A Molecular Crosstalk and Therapeutic Perspective,” International Immunopharmacology 159 (2025): 114902.

[316] Y. Liu, J. Ye, Z. Fan, et al., “Ginkgetin Alleviates Inflammation and Senescence by Targeting Sting,” Advanced Science (2024).

[317] M. H. Ha, M. S. Kim, H.-J. An, et al., “#5403 Pten-Induced Kinase 1 Has Association With Renal Aging Process Through the Cgas -Sting Pathway,” Nephrology Dialysis Transplantation (2023).

[318] H. L. Sladitschek-Martens, A. Guarnieri, G. Brumana, et al., “Yap/Taz Activity in Stromal Cells Prevents Ageing by Controlling Cgas–Sting,” Nature 607 (2022): 790–798.

[319] X. Yang, P. Liu, Y. Cui, et al., “T-2 Toxin Caused Mice Testicular Inflammation Injury via Ros-Mediated Nlrp3 Inflammasome Activation,” Journal of Agricultural and Food Chemistry 70 (2022): 14043–14051.

[320] R. Zhu, X. Mi, and Y. Li, “Effects of Hypoxic Environment on Periodontal Tissue Through the Ros/Txnip/Nlrp3 Inflammasome Pathway,” BioMed Research International 2022 (2022): 7690960.

[321] S. S. Iyer, Q. He, and J. R. Janczy, “Mitochondrial Cardiolipin Is Required for Nlrp3 Inflammasome Activation,” Immunity 39 (2013): 311–323.

[322] A. Cabral, J. E. Cabral, A. Wang, et al., “Differential Binding of Nlrp3 to Non-Oxidized and Ox-Mtdna Mediates Nlrp3 Inflammasome Activation,” Communications Biology 6, no. 1 (2023): 578.

[323] D. Wu, Y. Chen, Y. Sun, et al., “Target of Mcc950 in Inhibition of Nlrp3 Inflammasome Activation: A Literature Review,” Inflammation 43 (2020): 17–23.

[324] J. M. Navarro-Pando, E. Alcocer-Gómez, B. Castejón-Vega, et al., “Inhibition of the Nlrp3 Inflammasome Prevents Ovarian Aging,” Science Advances 7 (2021).

[325] M. Murakami, S. Osuka, A. Muraoka, et al., “Effectiveness of Nlrp3 Inhibitor as a Non-Hormonal Treatment for Ovarian Endometriosis,” Reproductive Biology and Endocrinology 20 (2022).

[326] L. Zhang, Y.-H. Jiang, C. Fan, et al., “Mcc950 Attenuates Doxorubicin-Induced Myocardial Injury in Vivo and in Vitro by Inhibiting Nlrp3-Mediated Pyroptosis,” Biomedicine & Pharmacotherapy 143 (2021): 112133.

[327] W. B. Liu, S. S. Wang, X. Zhang, et al., “Enhanced Cardiomyocyte Nlrp3 Inflammasome-Mediated Pyroptosis Promotes D-Galactose-Induced Cardiac Aging,” Journal of the American Heart Association 13, no. 14 (2024): e032904.

[328] L. Yang, X. Zhang, and Q. Wang, “Effects and Mechanisms of Sglt2 Inhibitors on the Nlrp3 Inflammasome, With a Focus on Atherosclerosis,” Frontiers in Endocrinology 13 (2022): 992937.

[329] A. Chen, Z. Lan, L. Li, et al., “Sglt2 Inhibitor Canagliflozin Alleviates Vascular Calcification Through Suppression of Nlrp3 Inflammasome,” Cardiovascular Research 119, no. 13 (2023): 2368–2381.

[330] S. Shang, L. Wang, Y. Zhang, et al., “The Beta-Hydroxybutyrate Suppresses the Migration of Glioma Cells by Inhibition of Nlrp3 Inflammasome,” Cellular and Molecular Neurobiology 38 (2018): 1479–1489.

[331] S. Luo, M. Yang, Y. Han, et al., “Β-Hydroxybutyrate Against Cisplatin-Induced Acute Kidney Injury via Inhibiting Nlrp3 Inflammasome and Oxidative Stress,” International Immunopharmacology 111 (2022): 109101.

[332] P. Zhang, H. Zhai, S. Zhang, et al., “Gdf11 Protects Against Mitochondrial-Dysfunction-Dependent Nlrp3 Inflammasome Activation to Attenuate Osteoarthritis,” Journal of Advanced Research 73 (2024): 501–515.

[333] Z. Zhang, T. Huang, X. Chen, et al., “Acetyl Zingerone Inhibits Chondrocyte Pyroptosis and Alleviates Osteoarthritis Progression by Promoting Mitophagy Through the Pink1/Parkin Signaling Pathway,” International Immunopharmacology 161 (2025): 115055.

[334] W. Shi, Q. Zhou, L. Lu, et al., “Copper Induced Cytosolic Escape of Mitochondrial DNA and Activation of Cgas-Sting-Nlrp3 Pathway-Dependent Pyroptosis in C8-D1a Cells,” Ecotoxicology and Environmental Safety 285 (2024): 117085.

[335] T. Wu, J. Gao, W. Liu, et al., “Nlrp3 Protects Mice From Radiation-Induced Colon and Skin Damage via Attenuating Cgas-Sting Signaling,” Toxicology and Applied Pharmacology 418 (2021): 115495.

[336] E. R. Zunica, C. L. Axelrod, E. Cho, et al., “Abstract 2145: Untargeted Sequencing of Human Breast Cancer Reveals Induction of Pro-Apoptotic and Anti-Proliferative Transcriptional Signatures in Response to Mitochondrial Uncoupling,” Cancer Research 81 (2021): 2145–2145.

[337] L. Rui, “New Antidiabetes Agent Targeting both Mitochondrial Uncoupling and Pyruvate Catabolism: Two Birds With One Stone,” Diabetes 68, no. 12 (2019): 2195–2196.

[338] W.-H. Cai, J. Fan, K. Zhou, et al., “Mitochondrial Division Inhibitor 1 Protects Cortical Neurons From Excitotoxicity: A Mechanistic Pathway,” Neural Regeneration Research 13 (2018): 1552.

[339] F. L. Wei, T. F. Wang, C. L. Wang, et al., “Cytoplasmic Escape of Mitochondrial DNA Mediated by Mfn2 Downregulation Promotes Microglial Activation via Cgas-Sting Axis in Spinal Cord Injury,” Advanced Science (2023).

[340] C. J. Anderson, A. Kahl, H. Fruitman, et al., “Prohibitin Levels Regulate Oma1 Activity and Turnover in Neurons,” Cell Death and Differentiation (2019).

[341] A. J. Grant, N. Yang, M. J. Moore, et al., “Selective Nlrp3 Inflammasome Inhibitor Mcc950 Suppresses Inflammation and Facilitates Healing in Vascular Materials,” Advanced Science 10, no. 20 (2023): e2300521.

[342] Y.-H. Youm, K. Y. Nguyen, R. W. Grant, et al., “The Ketone Metabolite Β-Hydroxybutyrate Blocks Nlrp3 Inflammasome-Mediated Inflammatory Disease,” Nature Medicine 21 (2015): 263–269.

[343] L. Ma, R. Wang, H. Wang, et al., “Long-Term Caloric Restriction Activates the Myocardial Sirt1/Ampk/Pgc-1α Pathway in C57bl/6j Male Mice,” Food & Nutrition Research 64 (2020).

[344] B. J. Gurd, E. S. Menezes, B. B. Arhen, and H. Islam, “Impacts of Altered Exercise Volume, Intensity, and Duration on the Activation of Ampk and Camkii and Increases in Pgc-1α Mrna,” Seminars in Cell & Developmental Biology (2022).

[345] Z. Wu, P. Puigserver, U. Andersson, et al., “Mechanisms Controlling Mitochondrial Biogenesis and Respiration Through the Thermogenic Coactivator Pgc-1,” Cell 98 (1999): 115–124.

[346] L. Chen, K. Shi, N. Ditzel, et al., “Kiaa1199 Deficiency Enhances Skeletal Stem Cell Differentiation to Osteoblasts and Promotes Bone Regeneration,” Nature Communications 14, no. 1 (2023): 2016.

[347] M. Li, Y. Yu, K. Xue, et al., “Genistein Mitigates Senescence of Bone Marrow Mesenchymal Stem Cells via Errα-Mediated Mitochondrial Biogenesis and Mitophagy in Ovariectomized Rats,” Redox Biology 61 (2023): 102649.

[348] Y. Guo, X. Jia, Y. Cui, et al., “Sirt3-Mediated Mitophagy Regulates Ages-Induced Bmscs Senescence and Senile Osteoporosis,” Redox Biology 41 (2021): 101915.

[349] K. Xu, J. Li, R. Wen, et al., “Role of Sirt3 in Bone Homeostasis and Its Application in Preventing and Treating Bone Diseases,” Frontiers in Pharmacology 14 (2023): 1248507.

[350] F.-S. Wang, R.-W. Wu, Y.-S. Chen, et al., “Biophysical Modulation of the Mitochondrial Metabolism and Redox in Bone Homeostasis and Osteoporosis: How Biophysics Converts Into Bioenergetics,” Antioxidants 10, no. 9 (2021): 1394.

[351] J. Liu, X. Zhang, H. Hou, et al., “Advances in Osteoblast and Mitochondrial Dynamics and Their Transfer in Osteoporosis,” Journal of Cellular and Molecular Medicine 28 (2024): e70299.

[352] C. Tang, J. Deng, R. Xu, et al., “Micro/Nano-Modified Titanium Surfaces Accelerate Osseointegration via Rab7-Dependent Mitophagy,” Biomaterials Science (2022).

[353] S. C. Broome, J. Whitfield, L. G. Karagounis, and J. A. Hawley, “Mitochondria as Nutritional Targets to Maintain Muscle Health and Physical Function during Ageing,” Sports Medicine 54 (2024): 2291–2309.

[354] A. E. Vincent, J. P. Grady, M. C. Rocha, et al., “Mitochondrial Dysfunction in Myofibrillar Myopathy,” Neuromuscular Disorders 26 (2016): 691–701.

[355] C. Hedberg-Oldfors, U. Lindgren, K. Visuttijai, et al., “Respiratory Chain Dysfunction in Perifascicular Muscle Fibres in Patients With Dermatomyositis Is Associated With Mitochondrial DNA Depletion,” Neuropathology and Applied Neurobiology 48 (2022): e12841.

[356] V. E. Jahnke, J. M. Peterson, J. H. Van Der Meulen, et al., “Mitochondrial Dysfunction and Consequences in Calpain-3-Deficient Muscle,” Skeletal Muscle 10, no. 1 (2020): 37.

[357] X. Hong, J. Isern, S. Campanario, et al., “Mitochondrial Dynamics Maintain Muscle Stem Cell Regenerative Competence throughout Adult Life by Regulating Metabolism and Mitophagy,” Cell Stem Cell 29 (2022): 1506–1508.

[358] J. Feige, “Nutritional Strategies to Counteract Mitochondrial Dysfunction and Nad+ Deficiency in Human Sarcopenia,” Innovation in Aging (2020).

[359] M. Membrez, E. Migliavacca, S. Christen, et al., “Trigonelline Is an Nad+ Precursor That Improves Muscle Function during Ageing and Is Reduced in Human Sarcopenia,” Nature Metabolism 6 (2024): 433–447.

[360] C. Vinel, L. Lukjanenko, A. Batut, et al., “The Exerkine Apelin Reverses Age-Associated Sarcopenia,” Nature Medicine 24 (2018): 1360–1371.

[361] W. S. Dantas, E. R. M. Zunica, E. C. Heintz, et al., “Mitochondrial Uncoupling Attenuates Sarcopenic Obesity by Enhancing Skeletal Muscle Mitophagy and Quality Control,” Journal of Cachexia, Sarcopenia and Muscle 13, no. 3 (2022): 1821–1836.

[362] Y. Yuan, J. Yang, A. Zhuge, et al., “Gut Microbiota Modulates Osteoclast Glutathione Synthesis and Mitochondrial Biogenesis in Mice Subjected to Ovariectomy,” Cell Proliferation 55 (2022): e13194.

[363] L. Su, Z. Feng, S. Liu, et al., “Nanoscale-Engineered Fluorescent Probe Reveals Impaired Mitochondria-Lysosome Crosstalk in Alzheimer's Disease,” Chemical Engineering Journal (2025).

[364] M. Song, X. Zhao, and F. Song, “Aging-Dependent Mitophagy Dysfunction in Alzheimer's Disease,” Molecular Neurobiology 58 (2021): 2362–2378.

[365] A. Misrani, S. Tabassum, and L. Yang, “Mitochondrial Dysfunction and Oxidative Stress in Alzheimer's Disease,” Frontiers in Aging Neuroscience 13 (2021).

[366] E. F. Fang, Y. Hou, K. Palikaras, et al., “Mitophagy Inhibits Amyloid-Β and Tau Pathology and Reverses Cognitive Deficits in Models of Alzheimer's Disease,” Nature Neuroscience 22 (2019): 401–412.

[367] S.-F. Xu, J.-H. Cui, X. Liu, et al., “Astrocytic Lactoferrin Deficiency Augments Mptp-Induced Dopaminergic Neuron Loss by Disturbing Glutamate/Calcium and Er-Mitochondria Signaling,” Free Radical Biology and Medicine 225 (2024): 374–387.

[368] Y. Hou, X. Chu, J. H. Park, et al., “Urolithin a Improves Alzheimer's Disease Cognition and Restores Mitophagy and Lysosomal Functions,” Alzheimer's & Dementia (2024).

[369] Y. Hou, Y. Wei, S. Lautrup, et al., “Nad+ Supplementation Reduces Neuroinflammation and Cell Senescence in a Transgenic Mouse Model of Alzheimer's Disease via Cgas-Sting [Neuroscience],” Proceedings of the National Academy of Sciences of the United States of America 118 (2021): e2011226118.

[370] A. Mary, F. Eysert, F. Checler, and M. Chami, “Mitophagy in Alzheimer's Disease: Molecular Defects and Therapeutic Approaches,” Molecular Psychiatry (2022).

[371] M. Safieh, A. D. Korczyn, and D. M. Michaelson, “Apoe4: An Emerging Therapeutic Target for Alzheimer's Disease,” BMC Medicine 17 (2019).

[372] A. C. Tecalco-Cruz, J. Zepeda-Cervantes, L. López-Canovas, et al., “Cellular Senescence and Apoe4: Their Repercussions in Alzheimer's Disease,” CNS & Neurological Disorders—Drug Targets 20, no. 9 (2021): 778–785.

[373] A. K. Rottner, A. Lundin, S. Li, et al., “Optimized Prime Editing of the Alzheimer's Disease-Associated Apoe4 Mutation,” Stem Cell Reports (2024).

[374] J. M. Vance, L. A. Farrer, Y. Huang, et al., “Report of the Apoe4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing Apoe4 in Carriers Is a Therapeutic Goal for Alzheimer's Disease,” Annals of Neurology 95 (2024): 625–634.

[375] A. B. Malpartida, M. Williamson, D. P. Narendra, et al., “Mitochondrial Dysfunction and Mitophagy in Parkinson's Disease: From Mechanism to Therapy,” Trends in Biochemical Sciences (2020).

[376] P. Song and D. Krainc, “Diverse Functions of Parkin in Midbrain Dopaminergic Neurons,” Movement Disorders 39, no. 8 (2024): 1282–1288.

[377] A. Bose and M. F. Beal, “Mitochondrial Dysfunction in Parkinson's Disease,” Journal of Neurochemistry 139 (2016): 216–231.

[378] S. M. Vastegani, A. Nasrolahi, S. Ghaderi, et al., “Mitochondrial Dysfunction and Parkinson's Disease: Pathogenesis and Therapeutic Strategies,” Neurochemical Research 48, no. 8 (2023): 2285–2308.

[379] R. Jain, N. Begum, K. P. Tryphena, et al., “Inter and Intracellular Mitochondrial Transfer: Future of Mitochondrial Transplant Therapy in Parkinson's Disease,” Biomedicine & Pharmacotherapy 159 (2023): 114268.

[380] M. Parmar, S. Grealish, and C. Henchcliffe, “The Future of Stem Cell Therapies for Parkinson Disease,” Nature Reviews Neuroscience 21 (2020): 103–115.

[381] Y. Aman, “Stem Cell Therapies for Parkinson's Disease,” Nature Aging 5 (2025): 727–727.

[382] H. Chamkouri, J. Si, P. Chen, et al., “Overcoming Challenges of Clinical Cell Therapies for Parkinson's Disease With Photobiomodulation,” Interdisciplinary Medicine 2, no. 3 (2024): e20240013.

[383] Y. Liu, Y. Huang, C. Xu, et al., “Mitochondrial Dysfunction and Therapeutic Perspectives in Cardiovascular Diseases,” International Journal of Molecular Sciences 23, no. 24 (2022): 16053.

[384] J. Yang, Q. Guo, X. Feng, et al., “Mitochondrial Dysfunction in Cardiovascular Diseases: Potential Targets for Treatment,” Frontiers in Cell and Developmental Biology (2022).

[385] S. M. Craige, G. Kaur, J. M. Bond, et al., “Endothelial Reactive Oxygen Species: Key Players in Cardiovascular Health and Disease,” Antioxidants & Redox Signaling (2024).

[386] C. Wu, Z. Zhang, W. Zhang, and X. Liu, “Mitochondrial Dysfunction and Mitochondrial Therapies in Heart Failure,” Pharmacological Research (2021).

[387] J. Hu, T. Liu, F. Fu, et al., “Omentin1 Ameliorates Myocardial Ischemia-Induced Heart Failure via Sirt3/Foxo3a-Dependent Mitochondrial Dynamical Homeostasis and Mitophagy,” Journal of Translational Medicine 20, no. 1 (2022): 447.

[388] R. A. Gioscia-Ryan, T. J. LaRocca, A. L. Sindler, et al., “Mitochondria-Targeted Antioxidant (Mitoq) Ameliorates Age-Related Arterial Endothelial Dysfunction in Mice,” The Journal of Physiology 592 (2014): 2549–2561.

[389] D. Graham, N. N. Huynh, C. A. Hamilton, et al., “Mitochondria-Targeted Antioxidant Mitoq10 Improves Endothelial Function and Attenuates Cardiac Hypertrophy,” Hypertension 54 (2009): 322–328.

[390] N. A. Holland, C. R. Fraiser, R. C. Sloan, et al., “Ultrafine Particulate Matter Increases Cardiac Ischemia/Reperfusion Injury via Mitochondrial Permeability Transition Pore,” Cardiovascular Toxicology 17 (2017): 441–450.

[391] Y. Zhao, Y. Guo, Y. Chen, et al., “Curculigoside Attenuates Myocardial Ischemia‑Reperfusion Injury by Inhibiting the Opening of the Mitochondrial Permeability Transition Pore,” International Journal of Molecular Medicine (2020).

[392] M. Panel, A. Ahmed-Belkacem, I. Ruiz, et al., “A Phenyl-Pyrrolidine Derivative Reveals a Dual Inhibition Mechanism of Myocardial Mitochondrial Permeability Transition Pore, Which Is Limited by Its Myocardial Distribution,” Journal of Pharmacology and Experimental Therapeutics 376 (2021): 348–357.

[393] A. Kheyar, N. Ahnou, A. Ahmed-Belkacem, et al., “The Novel Cyclophilin Inhibitor C105sr Reduces Hepatic Ischaemia–Reperfusion Injury via Mitoprotection,” JHEP Reports 5 (2023): 100876.

[394] Z. Zhou, W. Li, L. Ni, et al., “Icariin Improves Oxidative Stress Injury during Ischemic Stroke via Inhibiting Mptp Opening,” Molecular Medicine 30, no. 1 (2024): 77.

[395] Y. Yuan, H. Huang, T. Hu, et al., “Curcumin Pretreatment Attenuates Myocardial Ischemia/Reperfusion Injury by Inhibiting Ferroptosis, Autophagy and Apoptosis via Hes1,” International Journal of Molecular Medicine 54 (2024).

[396] H. A. Cabrera-Fuentes, M. Ruiz-Meana, G. Barreto, et al., “Extracellular Rna Drives Tnf-Α/Tnf-Receptor-1 Mediated Cardiac Ischemia/Reperfusion Injury: Mechanistic Insights and Therapeutic Potential of Rnase1,” Pharmacological Research 221 (2025): 107944.

[397] S. Deng, Y. Ren, Q. Zhang, et al., “Nanoengineered Mitochondria for Mitochondrial Dysfunction and Anti-Aging Interventions,” Frontiers in Aging 6 (2025).

[398] M. Li, L. Wu, H. Si, et al., “Engineered Mitochondria in Diseases: Mechanisms, Strategies, and Applications,” Signal Transduction and Targeted Therapy (2025).

[399] Q. Jiao, L. Xiang, and Y. Chen, “Mitochondrial Transplantation: A Promising Therapy for Mitochondrial Disorders,” International Journal of Pharmaceutics 658 (2024): 124194.

[400] Y. Huang, W. Li, H. Sun, et al., “Mitochondrial Transfer in the Progression and Treatment of Cardiac Disease,” Life Sciences 358 (2024): 123119.

[401] B. Wei, M. Ji, Y. Lin, et al., “Mitochondrial Transfer From Bone Mesenchymal Stem Cells Protects Against Tendinopathy both in Vitro and in Vivo,” Stem Cell Research & Therapy 14 (2023).

[402] T.-G. Zhang and C.-Y. Miao, “Mitochondrial Transplantation as a Promising Therapy for Mitochondrial Diseases,” Acta Pharmaceutica Sinica B (2022).

[403] R. Iorio, S. Petricca, G. Di Emidio, et al., “Mitochondrial Extracellular Vesicles (Mitoevs): Emerging Mediators of Cell-to-Cell Communication in Health, Aging and Age-Related Diseases,” Ageing Research Reviews 101 (2024): 102522.

[404] L. H. Fairley, A. Grimm, and A. Eckert, “Mitochondria Transfer in Brain Injury and Disease,” Cells 11 (2022): 3603.

[405] R. Iorio, S. Petricca, V. Mattei, and S. Delle Monache, “Horizontal Mitochondrial Transfer as a Novel Bioenergetic Tool for Mesenchymal Stromal/Stem Cells: Molecular Mechanisms and Therapeutic Potential in a Variety of Diseases,” Journal of Translational Medicine 22 (2024).

[406] K. Malekpour, A. Hazrati, S. Soudi, and S. M. Hashemi, “Mechanisms behind Therapeutic Potentials of Mesenchymal Stem Cell Mitochondria Transfer/Delivery,” Journal of Controlled Release 354 (2023): 755–769.

[407] Y. Wang, H.-Y. Yu, Z.-J. Yi, et al., “Super Mitochondria-Enriched Extracellular Vesicles Enable Enhanced Mitochondria Transfer,” Nature Communications 16, no. 1 (2025): 9448.

[408] Y. Chen, H. Sun, Y. Li, et al., “Magnetic Nanomaterials for Hyperthermia-Based Therapy and Controlled Drug Delivery,” Bioactive Materials (2025).

[409] Z. Wu, L. Chen, W. Guo, et al., “Oral Mitochondrial Transplantation Using Nanomotors to Treat Ischaemic Heart Disease,” Nature Nanotechnology (2024).

[410] K. Reinhardt, D. K. Dowling, and E. H. Morrow, “Mitochondrial Replacement, Evolution, and the Clinic,” Science 341 (2013): 1345–1346.

[411] B. Y. Mok, M. H. de Moraes, J. Zeng, et al., “A Bacterial Cytidine Deaminase Toxin Enables Crispr-Free Mitochondrial Base Editing,” Nature 583 (2020): 631–637.

[412] K. Lim, S.-I. Cho, and J.-S. Kim, “Nuclear and Mitochondrial DNA Editing in Human Cells With Zinc Finger Deaminases,” Nature Communications 13 (2022).

[413] S.-I. Cho, S. Lee, Y. G. Mok, et al., “Targeted a-to-G Base Editing in Human Mitochondrial DNA With Programmable Deaminases,” Cell 185 (2022): 1764–1776.e12.

[414] H. T. L. Phan, H. Lee, and K. Kim, “Trends and Prospects in Mitochondrial Genome Editing,” Experimental & Molecular Medicine 55 (2023): 871–878.

[415] S.-I. Cho, K. Lim, S. Hong, et al., “Engineering Tale-Linked Deaminases to Facilitate Precision Adenine Base Editing in Mitochondrial DNA,” Cell 187 (2024): 95–109.e26.

[416] Y. Fan, W. Xu, B.-Q. Gao, et al., “Leveraging Base Excision Repair for Efficient Adenine Base Editing of Mitochondrial DNA,” Nature Biotechnology (2025).

[417] Y. Wei, M. Jin, S. Huang, et al., “Enhanced C-to-T and a-to-G Base Editing in Mitochondrial DNA With Engineered Ddcbe and Taled,” Advanced Science (2023).

[418] Y. Zhou, Y. Jin, T. Wu, et al., “New Insights on Mitochondrial Heteroplasmy Observed in Ovarian Diseases,” Journal of Advanced Research (2023).

[419] N. Nissanka and C. T. Moraes, “Mitochondrial DNA Heteroplasmy in Disease and Targeted Nuclease-Based Therapeutic Approaches,” EMBO Reports 21 (2020).

[420] U. Zekonyte, S. R. Bacman, and C. T. Moraes, “DNA-Editing Enzymes as Potential Treatments for Heteroplasmic Mtdna Diseases,” Journal of Internal Medicine 287 (2020): 685–697.

[421] S. Millington-Ward, N. Chadderton, L. K. Finnegan, et al., “Aav-Mediated Gene Therapy Improving Mitochondrial Function Provides Benefit in Age-Related Macular Degeneration Models,” Clinical and Translational Medicine 12 (2022): e952.

[422] X. Li, S. La Salvia, and Y. Liang, “Extracellular Vesicle-Encapsulated Adeno-Associated Viruses for Therapeutic Gene Delivery to the Heart,” Circulation 148, no. 5 (2023): 405–425.

[423] T. DeVine, G. Elizondo, G. Gaston, et al., “Ipsc-Derived Lchadd Retinal Pigment Epithelial Cells Are Susceptible to Lipid Peroxidation and Rescued by Transfection of a Wildtype Aav-Hadha Vector,” Investigative Ophthalmology & Visual Science 65 (2024): 22.

[424] S. He, Z. Li, L. Xie, et al., “Biomimetic Gene Delivery System Coupled With Extracellular Vesicle–Encapsulated Aav for Improving Diabetic Wound Through Promoting Vascularization and Remodeling of Inflammatory Microenvironment,” Journal of Nanobiotechnology 23 (2025).

[425] K. Y. Kim, H. Jin, J. Park, et al., “Mitochondria-Targeting Self-Assembled Nanoparticles Derived From Triphenylphosphonium-Conjugated Cyanostilbene Enable Site-Specific Imaging and Anticancer Drug Delivery,” Nano Research (2017).

[426] S. Sivagnanam, K. Das, I. Pan, et al., “Engineered Triphenylphosphonium-Based, Mitochondrial-Targeted Liposomal Drug Delivery System Facilitates Cancer Cell Killing Actions of Chemotherapeutics,” RSC Chemical Biology (2023).

[427] Y. Han, C. Gao, H. Wang, et al., “Macrophage Membrane-Coated Nanocarriers Co-Modified by Rvg29 and Tpp Improve Brain Neuronal Mitochondria-Targeting and Therapeutic Efficacy in Alzheimer's Disease Mice,” Bioactive Materials (2021).

[428] W. Zhou, H. Yu, L.-J. Zhang, et al., “Redox-Triggered Activation of Nanocarriers for Mitochondria-Targeting Cancer Chemotherapy,” Nanoscale (2017).

[429] H. B. Ruttala, T. Ramasamy, R. R. T. Ruttala, et al., “Mitochondria-Targeting Multi-Metallic Zncuo Nanoparticles and Ir780 for Efficient Photodynamic and Photothermal Cancer Treatments,” Journal of Materials Science & Technology 86 (2021): 139–150.

[430] L. Yang, H. Ran, Y. Yin, et al., “Mitochondrial Targeted Cerium Oxide Nanoclusters for Radiation Protection and Promoting Hematopoiesis,” International Journal of Nanomedicine 19 (2024): 6463–6483.

[431] H. Yu, F. Jin, D. Liu, et al., “Ros-Responsive Nano-Drug Delivery System Combining Mitochondria-Targeting Ceria Nanoparticles With Atorvastatin for Acute Kidney Injury,” Theranostics 10 (2020): 2342–2357.

[432] W. Wang, X. Xu, Y. Song, et al., “Nano Transdermal System Combining Mitochondria-Targeting Cerium Oxide Nanoparticles With All-Trans Retinoic Acid for Psoriasis,” Asian Journal of Pharmaceutical Sciences 18 (2023): 100846.

[433] F. Eiras, M. H. Amaral, R. Silva, et al., “Characterization and Biocompatibility Evaluation of Cutaneous Formulations Containing Lipid Nanoparticles,” International Journal of Pharmaceutics 519 (2017): 373–380.

[434] W. Zhang, J. Li, N. Wang, et al., “Lung-Targeted Polyzwitterionic Lipid Nanoparticles for Effective Treatment of Lung Inflammation,” Science China Chemistry (2025).

[435] X. Niu, J. Zhang, J. Zhang, et al., “Lipid Nanoparticle-Mediated Oip5-As1 Delivery Preserves Mitochondrial Function in Myocardial Ischemia/Reperfusion Injury by Inhibiting the P53 Pathway,” ACS Applied Materials & Interfaces 16 (2024): 61565–61582.

[436] Y. Yamada, R. Furukawa, Y. Yasuzaki, and H. Harashima, “Dual Function Mito-Porter, a Nano Carrier Integrating both Efficient Cytoplasmic Delivery and Mitochondrial Macromolecule Delivery,” Molecular Therapy (2016).

[437] Y. Yamada, T. Ishikawa, and H. Harashima, “Validation of the Use of an Artificial Mitochondrial Reporter DNA Vector Containing a Cytomegalovirus Promoter for Mitochondrial Transgene Expression,” Biomaterials 136 (2017): 56–66.

[438] M. Hibino, T. Filosi, L. L. Carrion, et al., “An Effective Approach to Modulate Mitochondrial Function in Murine Primary Macrophages by a Mitochondria-Targeted Nanocapsule, Mito-Porter,” Biomedicine & Pharmacotherapy 186 (2025): 118019.

[439] R. Furukawa, Y. Yamada, E. Kawamura, and H. Harashima, “Mitochondrial Delivery of Antisense Rna by Mito-Porter Results in Mitochondrial Rna Knockdown, and Has a Functional Impact on Mitochondria,” Biomaterials 57 (2015): 107–115.

[440] X. Gao, M. Zhang, S. Du, et al., “Engineering a Spleen-Selective Mrna-Lnps Vaccine by Decoupling the Inflammation From Cellular Immunity-Mediated Cancer Immunotherapy,” Theranostics 15 (2025): 9643–9662.

[441] D. A.-O. Kirkman, J. A.-O. X. Stock, N. A.-O. Shenouda, et al., “Effects of a Mitochondrial-Targeted Ubiquinol on Vascular Function and Exercise Capacity in Chronic Kidney Disease: A Randomized Controlled Pilot Study,” Translated by J. P. R. P. Am. no. 1522-1466 (Electronic).

[442] A. Karaa, E. Bertini, V. Carelli, et al., “Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The Mmpower-3 Randomized Clinical Trial,” Neurology 101 (2023): e238–e252.

[443] A. Guariento, B. L. Piekarski, I. P. Doulamis, et al., “Autologous Mitochondrial Transplantation for Cardiogenic Shock in Pediatric Patients Following Ischemia-Reperfusion Injury,” The Journal of Thoracic and Cardiovascular Surgery (2020).

[444] D. Samanta and G. L. Semenza, “Maintenance of Redox Homeostasis by Hypoxia-Inducible Factors,” Redox Biology 13 (2017): 331–335.

[445] D. Bou-Teen, C. Fernandez-Sanz, E. Miro-Casas, et al., “Defective Dimerization of Fof1-Atp Synthase Secondary to Glycation Favors Mitochondrial Energy Deficiency in Cardiomyocytes during Aging,” Aging Cell 21 (2022).

[446] Y. Yan, L.-Y. Tian, and Q. Jia, “Mir-130a-3p Regulates Fundc1-Mediated Mitophagy by Targeting Gja1 in Myocardial Ischemia/Reperfusion Injury,” Cell Death Discovery (2023).

[447] M. Fiorenza, A. K. Lemminger, M. Marker, et al., “High-Intensity Exercise Training Enhances Mitochondrial Oxidative Phosphorylation Efficiency in a Temperature-Dependent Manner in Human Skeletal Muscle: Implications for Exercise Performance,” The FASEB Journal 33 (2019): 8976–8989.

[448] S. Kaiser, L. Zhang, B. Mollenhauer, et al., “A Proteogenomic View of Parkinson's Disease Causality and Heterogeneity,” npj Parkinson's Disease (2023).

[449] Y. Chen, T. T. Lam, X. Yu, and V. Vasiliou, “Differential Redox Changes in Liver Mitochondrial Proteomes From Phenotypically Distinct Mouse Models of Glutathione Deficiency,” Free Radical Biology and Medicine (2017).

[450] P. Chen, L. Yao, M. Yuan, et al., “Mitochondrial Dysfunction: A Promising Therapeutic Target for Liver Diseases,” Genes & Diseases (2023).

[451] E. Mansell, V. Sigurdsson, E. Deltcheva, et al., “Mitochondrial Potentiation Ameliorates Age-Related Heterogeneity in Hematopoietic Stem Cell Function,” Cell Stem Cell (2020).

[452] M. Li, R. Schröder, S. Ni, et al., “Extensive Tissue-Related and Allele-Related Mtdna Heteroplasmy Suggests Positive Selection for Somatic Mutations,” Proceedings of the National Academy of Sciences of the United States of America (2015).

[453] D. Fang, Z. Zhang, H. Li, et al., “Increased Electron Paramagnetic Resonance Signal Correlates With Mitochondrial Dysfunction and Oxidative Stress in an Alzheimer's Disease Mouse Brain,” Journal of Alzheimer's Disease 51 (2016): 571–580.

[454] K. Thomsen, T. Yokota, M. M. Hasan-Olive, et al., “Initial Brain Aging: Heterogeneity of Mitochondrial Size Is Associated With Decline in Complex I-Linked Respiration in Cortex and Hippocampus,” Neurobiology of Aging 61 (2018): 215–224.

[455] J. B. Michaelis, M. E. Brunstein, S. Bozkurt, et al., “Protein Import Motor Complex Reacts to Mitochondrial Misfolding by Reducing Protein Import and Activating Mitophagy,” Nature Communications 13 (2022).

[456] D. Dutta, R. Calvani, R. Bernabei, et al., “Contribution of Impaired Mitochondrial Autophagy to Cardiac Aging: Mechanisms and Therapeutic Opportunities,” Circulation Research 110 (2012): 1125–1138.

[457] A. H. Khan, X. Gu, R. J. Patel, et al., “Mitochondrial Protein Heterogeneity Stems From the Stochastic Nature of Co-Translational Protein Targeting in Cell Senescence,” Nature Communications 15 (2024).

[458] V. S. Marsden, L. O'Connor, L. A. O'Reilly, et al., “Apoptosis Initiated by Bcl-2-Regulated Caspase Activation Independently of the Cytochrome C/Apaf-1/Caspase-9 Apoptosome,” Nature 419 (2002): 634–637.

[459] A. Nasca, A. Legati, M. Meneri, et al., “Biallelic Variants in Endog Associated With Mitochondrial Myopathy and Multiple Mtdna Deletions,” Cells 11 (2022): 974.

[460] M. S. Rotunno, M. Lane, W. Zhang, et al., “Cerebrospinal Fluid Proteomics Implicates the Granin Family in Parkinson's Disease,” Scientific Reports 10 (2020).

[461] L. E. Eidem, E. Birkeland, M. Austdal, et al., “Fatigue in Parkinson's Disease: A Proteomic Study of Cerebrospinal Fluid,” Movement Disorders 39 (2024): 749–751.

[462] H.-X. Zheng, S. Yan, M. Zhang, et al., “Mitochondrial DNA Genomes Reveal Relaxed Purifying Selection during Human Population Expansion After the Last Glacial Maximum,” Molecular Biology and Evolution 41 (2024).

[463] J. Faitg, T. Davey, R. Laws, et al., “Mapping Mitochondrial Morphology and Function: Cox-Sbfsem Reveals Patterns in Mitochondrial Disease,” Communications Biology 8 (2025).

[464] H.-J. Kim, D.-W. Jung, and D. R. Williams, “Age Is Just a Number: Progress and Obstacles in the Discovery of New Candidate Drugs for Sarcopenia,” Cells 12 (2023): 2608.

[465] J. Zhang, L. Gu, Y. Jiang, et al., “Artesunate-Nanoliposome-Tpp, a Novel Drug Delivery System That Targets the Mitochondria, Attenuates Cisplatin-Induced Acute Kidney Injury by Suppressing Oxidative Stress and Inflammatory Effects,” International Journal of Nanomedicine (2024).

[466] Y. Li, X.-M. Li, L.-S. Wei, and J.-F. Ye, “Advancements in Mitochondrial-Targeted Nanotherapeutics: Overcoming Biological Obstacles and Optimizing Drug Delivery,” Frontiers in Immunology (2024).

[467] S. K. Misra, J. M. Rosenholm, and K. Pathak, “Functionalized and Nonfunctionalized Nanosystems for Mitochondrial Drug Delivery With Metallic Nanoparticles,” Molecules 28 (2023): 4701.

[468] M. Paillard, M. Abdellatif, I. Andreadou, et al., “Mitochondrial Targets in Ischaemic Heart Disease and Heart Failure, and Their Potential for a More Efficient Clinical Translation. A Scientific Statement of the Esc Working Group on Cellular Biology of the Heart and the Esc Working Group on Myocardial Function,” European Journal of Heart Failure (2025).

[469] L. Milane, M. Trivedi, A. Singh, et al., “Mitochondrial Biology, Targets, and Drug Delivery,” Journal of Controlled Release 207 (2015): 40–58.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.